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ABSTRACT 
Mary Ashley Sobran: Understanding the Regulatory Dynamic of the Two-Component Systems, 
PlrSR and BvgAS, During Bordetella Colonization of the Mammalian Respiratory Tract 
(Under the direction of Peggy A. Cotter) 
 
Pertussis is a severe respiratory disease caused by the bacterium Bordetella pertussis. 
Despite high vaccination coverage, the number of pertussis cases has rebounded in recent years. 
To combat this disease, more efficacious vaccines and improved knowledge of Bordetella 
virulence is critical. Bacteria often use two-component systems (TCSs) to coordinate essential 
cellular processes in response to the diverse environments they encounter. In B. pertussis and the 
closely related subspecies B. bronchiseptica, the TCS, BvgAS, controls the expression of almost 
all known virulence factor-encoding genes and is considered the main virulence regulatory 
system. Recently, another TCS, PlrSR, was identified that is also required for Bordetella 
infection within the lower respiratory tract (LRT). However, why PlrSR is important for 
colonization is unknown. Using engineered strains of B. bronchiseptica and genetic reporters, we 
demonstrated that PlrS is required for the maintenance of BvgAS activity in the lungs of mice, 
indicating that PlrSR, along with BvgAS, coordinates virulence specifically in the LRT. 
Moreover, our data indicate that PlrSR may regulate genes that are required for persistence in the 
LRT independent of BvgAS. Importantly, these genes and their corresponding proteins may 
serve as new vaccine components or therapeutic targets. We have also shown that the Per-Arnt-
Sim (PAS) domain of BvgS is required for BvgS inactivation in the absence of PlrS, indicating 
that the PAS domain is important for the PlrSR-BvgAS connection and functions as an 
independent signaling domain. Based on published data and our findings, we hypothesize that 
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PlrSR controls the expression of high-affinity cytochrome oxidases (HACOs) that are required 
for bacterial respiration and maintenance of BvgAS activity in the LRT. We have demonstrated 
that two of four HACOs contribute to LRT colonization. However, BvgAS activity is unaffected 
by the loss of these HACOs and it is unknown if PlrSR regulates the expression of any HACO 
encoding genes. Together, this work provides a more detailed understanding of the coordinated 
regulation imposed by PlrSR and BvgAS to promote Bordetella survival within the mammalian 
host.
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CHAPTER 1. INTRODUCTION 
Introduction 
Current pertussis vaccines fail to protect individuals from Bordetella pertussis colonization 
and pertussis disease 
Pertussis is a highly contagious and severe respiratory disease caused by the bacterium 
Bordetella pertussis (1). Despite high rates of vaccination, pertussis has reemerged as an urgent 
public health threat (2). During the late 1940s, a whole cell pertussis vaccine was introduced that 
dramatically reduced the incidence of pertussis (3). However, due to concerns over safety, the 
whole cell vaccine was replaced with an acellular pertussis vaccine. The current acellular vaccine 
contains only purified bacterial proteins and inactivated toxins, which serve as critical virulence 
factors for the bacteria. Since the transition from the whole cell to the acellular vaccine, the 
number of pertussis cases has rebounded. Studies have shown that the immunity generated by the 
current acellular vaccine is less robust and wanes faster compared to the immunity generated by 
pertussis infection or the whole cell vaccine (4–6).  As a result, the number of cases of pertussis 
reported in adolescence and young adults has increased (2). Recent studies using a baboon 
infection model demonstrate that although the acellular and whole cell vaccines provide 
protection against overt disease, they fail to prevent colonization of Bordetella within the 
respiratory tract (7). Moreover, animals immunized with the acellular vaccine were still able to 
transmit Bordetella to naïve animals (7–10). If true for human disease, current vaccination 
strategies may be inadvertently increasing the reservoir of Bordetella pertussis in the population, 
consequently putting unimmunized individuals, particularly infants, at elevated risk for infection. 
Thus, more efficacious vaccines are needed.  
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Despite high rates of vaccination, pertussis remains a burden in the United States and 
throughout the world 
In the Unites States, five doses of the pertussis vaccine (DTap) are recommended for all 
individuals by the age of seven and booster doses are recommended for adolescence and adults 
(11). Vaccination is also recommended for women during every pregnancy and breastfeeding is 
encouraged in hopes of transferring maternal immunity to infants, who are more at risk for fatal 
infections (12). In 2017, the median acellular pertussis vaccination coverage in the United States 
was 95.1%, almost 10% above the global average (13–15). However, approximately 19,000 
cases of pertussis were still reported, including 13 pertussis-associated deaths. Each year since 
the 1990s, the total number of pertussis cases has steadily increased, and multiple outbreaks have 
been reported across the country. Worldwide, the burden of pertussis is even greater with 
approximately 144,000 incidence of pertussis and 90,000 deaths resulting from pertussis 
infection reported in 2017 alone (14, 15).   
The progression of pertussis disease is most severe in young patients and can last for many 
months 
Pertussis illness can manifest as a range of symptoms from mild upper respiratory tract 
disease to severe, persistent, and progressive coughing that can continue for weeks or months (1, 
16). Following infection, progression of the disease can be categorized into three consecutive 
stages: the catarrhal stage, paroxysmal stage, and convalescent stage. During the catarrhal stage, 
which can last 1-2 weeks, symptoms are often mild and mistaken for those of a common cold, 
such as malaise, sore throat, nasal congestion, rhinorrhea, sneezing, and mild progressive dry 
cough. As a consequence, it often is not until the second stage of disease that pertussis is 
diagnosed. In the paroxysmal stage, patients often experience intense periods of severe coughing 
accompanied by inspiratory whoops. This symptom is the classic sign of pertussis and is the 
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reason for its alternative name, ‘Whooping Cough’. Other symptoms associated with this stage 
are cyanosis, eye proptosis, tongue protrusion, salivation, and thick oral mucus production. The 
paroxysmal stage is the longest in the progression of pertussis and can often last for two months.  
For younger patients, this stage is often the most dangerous due to the development of severe 
pulmonary hypertension and hypoxia due to apnea, which can lead to respiratory failure or death 
(16, 17). Hospitalization is required for severe cases at this stage. Convalescence is the final 
stage of pertussis disease and can be characterized by a decrease in coughing spams severity, 
duration, and frequency, however, mild coughing can last up to an additional 6 weeks. Moreover, 
individuals are more susceptible to secondary viral infections, which can cause a relapse of 
severe respiratory symptoms (1). Overall, pertussis disease progression and recovery can last 
many months making the burden of this disease immense.  
Bordetella pertussis produces many essential virulence factors during human infection 
Many virulence factors are required for successful colonization of B. pertussis in the 
human respiratory tract. Primarily these include several surface exposed and secreted factors, 
such as adhesins and toxins (18, 19). The primary adhesins, filamentous hemagglutinin (FHA) 
and fimbriae (FIM), are required for tracheal colonization and help to facilitate localization and 
adherence of the bacteria to the large airways, specifically the tracheal epithelium surface (18, 
20–22). Similarly, pertactin (PRN), a member of the classical autotransporter family of outer 
membrane proteins, has also been implicated as being important for bacterial adherence to 
ciliated epithelium (18, 23). Various toxins secreted by Bordetella are also essential for robust 
tracheal colonization and can disrupt the immune system response allowing the bacteria to evade 
phagocytosis and other bactericidal insults during infection. The most well studied of these 
toxins include pertussis toxin (PT), an ADP-ribosylating AB5-type toxin that induces 
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lymphocytosis during infection (18, 24–26), adenylate cyclase toxin (ACT), a calmodulin-
dependent RTX family toxin with dual adenylate cyclase and hemolysin activity (18, 27–29), 
and a type three secretion system (T3SS), which injects into host cells toxin effector proteins that 
are capable of inducing necrotic cell death and dampening the immune response in the lungs 
(30–34). Current formulations of the acellular vaccine used in the United States contain a 
combination of purified FHA, FIM, inactivated PT, and PRN (35). B. bronchiseptica, a closely 
related sub-species to B. pertussis that can infect a broad range of mammalian hosts, also 
produces a very similar, often functionally complementary, set of virulence factors that are 
essential for infection, except for PT (18, 19, 36, 37). In fact, due to its ability to naturally to 
infect pigs, rabbits, rats, and mice, the importance of many virulence factors has been evaluated 
using B. bronchiseptica and natural host animal models (22, 23, 33, 38).  
The complex, two-component phosphorelay system, BvgAS, is essential for Bordetella 
colonization of the mammalian host and is considered the master regulator of virulence 
All known protein virulence factor-encoding genes, including those encoding proteins 
present in current acellular vaccines, are regulated at the level of transcription by the two-
component system (TCS) BvgAS (39–42). The activity of this system is essential for bacterial 
colonization, persistence, and infection within the respiratory tract of the mammalian host and as 
such, BvgAS is considered the master regulator of Bordetella virulence (41, 43–47). This is true 
for both B. pertussis and B. bronchiseptica, which produce functionally interchangeable BvgAS 
systems (48).  
The BvgAS system is composed of two proteins. BvgS is a membrane localized, 
polydomain, His-Asp-His sensor kinase that phosphorylates its cognate DNA-binding response 
regulator, BvgA (42, 49–51). BvgS contains two periplasmic N-terminal sensory perception, 
venus flytrap domains, which are followed by a transmembrane domain, a cytoplasmically-
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located Per-Arnt-Sim (PAS) domain, a histidine kinase (HK) domain, a receiver (REC) domain, 
and finally a histidine phospho-transfer (Hpt) domain. When BvgS is activated, protein dimers 
undergo autophosphorylation at histidine residue 729 in the HK domain (51). The resulting 
phosphoryl group is subsequently transferred down the protein to conserved aspartic acid and 
histidine residues in the REC and Hpt domains, respectively. The Hpt domain then trans-
phosphorylates BvgA at aspartic acid residue 54 within the response regulators REC domain. 
Once phosphorylated, BvgA~P can dimerize and bind DNA via its C-terminal helix-turn-helix 
(HTH) domain to promote or repress gene expression (51–56). The BvgAS phosphorelay can 
also be reversed, however, and BvgS can dephosphorylate BvgA~P and inactivate the regulator 
protein (57). When BvgS dephosphorylates BvgA~P, the Hpt domain removes the phosphoryl 
group from BvgA, which then gets transferred to the REC domain of BvgS. The phosphoryl 
group is then donated to water to form inorganic phosphate.  
Due to the complex domain structure and function of BvgAS, this system has the ability 
to control the expression of four distinct classes of genes and three distinct phenotypic phases of 
the bacteria (18, 39, 41, 43, 44, 46, 53). When Bordetella are grown at 37˚C in the laboratory on 
Bordet-Gengou (BG) agar or in Stainer-Scholte (SS) broth, BvgS acts as a kinase, resulting in 
high levels of BvgA~P, and the bacteria express Bvg+ phase (58, 59). This phase is characterized 
by maximal expression of genes that are transcriptionally activated by BvgA~P, termed 
virulence activated genes or vags (Class 1 and 2 genes), and by maximal repression of virulence 
repressed genes or vrgs (Class 4 genes) (39, 46). All known virulence factor encoding genes are 
maximally expressed during the Bvg+ phase, including bvgAS. When BvgS acts as a 
phosphatase, resulting in low levels of BvgA~P, the bacteria express Bvg– phase; virulence gene 
expression is repressed, and vrgs are derepressed. In B. bronchiseptica, genes encoding flagella 
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are expressed in Bvg– phase and this phase, in B. bronchiseptica specifically, has been 
hypothesized to be important for bacterial survival in environments outside of a mammalian host 
(46, 60, 61). Bordetella express the Bvg– phase in vitro when grown in the presence of 
millimolar concentrations of nicotinic acid (NA) or magnesium sulfate (MgSO4) (62–64). When 
BvgS is partially active, generating intermediate levels of BvgA~P in the cell, the Bvgi phase is 
expressed (44, 52, 65). This phase is characterized by maximal expression of intermediate phase 
genes (Class 3 genes), such as bipA, repression of vrgs, and the expression of vags with high 
affinity BvgA~P promoter binding sites. Vags with high affinity BvgA~P promoters, termed 
‘early’ BvgA-activated genes or Class 2 genes, are expressed upon initial activation of BvgS (52, 
53, 55, 66) and once the level of BvgA~P has sufficiently accumulated in the cell, ‘late’ BvgA 
activated genes, or Class 1 genes, with low affinity BvgA~P promoter binding sites are activated. 
Despite our knowledge of how to manipulate BvgAS activity in vitro, the true signals that 
influence BvgS activity in nature are unknown.  
Although the importance of BvgAS for Bordetella virulence has been well established, the 
contributions of other two-component systems to bacterial survival and virulence in the 
mammalian host is less understood 
BvgS kinase activity and thus the Bvg+ phase is essential for Bordetella infection (44, 46, 
47, 50, 67, 68). Without BvgS (∆bvgS), bacteria express Bvg– phase and are rapidly cleared from 
the upper and lower (LRT) respiratory tract. Experiments with phase-locked and ectopic 
expression mutants have led to the conclusion that BvgAS is both necessary and sufficient for 
bacterial survival in the host (46, 68). Due to the importance of the BvgAS for Bordetella 
pathogenesis, great efforts have been made to characterize the mechanism of signal transduction 
and regulon of this system. As a consequence, however, little is known about how the other, 
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approximately 20, putative two-component system encoded in the genome contribute to 
Bordetella gene regulation and pathogenesis.   
PlrSR is a newly identified putative two-component system required for B. bronchiseptica 
colonization of the lower respiratory tract in rats 
Recently, another putative TCS has been identified that is required for Bordetella 
persistence, specifically within the LRT (38). This system is composed of a putative sensor 
kinase, PlrS, and a DNA binding response regulator, PlrR. The genes encoding PlrSR are highly 
conserved among pathogenic Bordetella and are 99% homologous between B. pertussis and B. 
bronchiseptica, suggesting the importance of this system for Bordetella gene regulation. In a rat 
model of colonization, B. bronchiseptica containing mutations predicted to abrogate PlrS kinase 
activity is rapidly cleared from the LRT similar to ∆bvgS mutants (38). Attempts to delete plrR 
have been unsuccessful, suggesting that PlrR is essential (at least under standard laboratory 
growth conditions). In addition, our collaborators have observed an increase in BvgAS-
dependent virulence factor production in B. bronchiseptica when grown with 5% CO2 depends 
on plrS, suggesting that PlrS influences BvgAS activity (69). However, the contribution of the 
PlrSR system to Bordetella colonization of the mammalian host is currently unknown.  
Research Objective 
For this dissertation, my objective was to understand why the putative PlrSR two-
component system is essential for Bordetella colonization and survival specifically within the 
mammalian lower respiratory tract. In Chapter 2, we demonstrate that PlrS is required for the 
maintenance of BvgAS activity in the lungs of mice, indicating that PlrSR, and not BvgAS, 
coordinates virulence specifically in the LRT. Moreover, our data indicate that PlrSR may 
regulate genes that are required for persistence in the LRT independent of BvgAS. We also 
show, in Chapter 3, that the Per-Arnt-Sim (PAS) domain of BvgS is required for BvgS 
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inactivation in the absence of PlrS in the LRT, indicating that the PAS domain is important for 
the PlrSR-BvgAS connection and functions as an independent signaling domain. In Chapter 4, 
we hypothesize that PlrSR controls the expression of high-affinity cytochrome oxidases 
(HACOs) that are required for bacterial respiration and maintenance of BvgAS activity in the 
LRT. We demonstrate that two of four HACOs contribute to LRT colonization. However, 
BvgAS activity is unaffected by the loss of these HACOs and it is unknown if PlrSR regulates 
the expression of any HACO encoding genes. Overall, this body of work contributes to the 
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CHAPTER 2. THE BORDETELLA PLRSR REGULATORY SYSTEM CONTROLS 
BVGAS ACTIVITY AND VIRULENCE IN THE LOWER RESPIRATORY TRACT1 
Introduction 
Caused by the human-specific, Gram-negative bacterium Bordetella pertussis, whooping 
cough (aka pertussis) is reemerging in the United States and other developed countries despite 
high vaccine coverage (1, 2). Increased incidence in recent years coincides with the switch to 
acellular vaccines, which induce immunity that is less durable than that induced by whole cell 
vaccines or by infection with B. pertussis (3-5) . Although closely related to B. pertussis, 
Bordetella bronchiseptica infects nearly all mammals and typically causes more chronic, long-
term respiratory infections (6). Despite these differences, B. pertussis and B. bronchiseptica 
produce a nearly identical set of virulence factors that includes adhesins, such as filamentous 
hemagglutinin (FHA) and fimbriae (FIM), and toxins, such as adenylate cyclase toxin (ACT) and 
a Type III Secretion System (T3SS) (2).  
The BvgAS phosphorelay-type two component regulatory system (TCS) is considered the 
‘master virulence control system’ in Bordetella. BvgAS differentially regulates (either directly or 
indirectly) hundreds of genes and at least three distinct phenotypic phases (7, 8). The Bvg+ phase 
occurs when the bacteria are grown at 37°C in Stainer-Scholte (SS) broth or on Bordet-Gengou 
                                                     
1 This chapter previously appeared as an article in PNAS. The original citation is as follows: M. Ashley Bone, Aaron 
J. Wilk, Andrew I. Perault, Sara A. Marlatt, Erich V. Scheller, Rebecca Anthouard, Qing Chen, Scott Stibitz, Peggy 
A. Cotter, Steven M. Julio. “Bordetella PlrSR regulatory system controls BvgAS activity and virulence in the lower 
respiratory tract” PNAS. 2017 Feb 21;114 (8) E1519-E1527; DOI:10.1073/pnas.1609565114. MAB contributed to 
this manuscript by assisting in the design, performance, and analysis of all research represented in figures 3-5, S4 
and S7. MAB compiled and formatted all figures and tables, wrote the results and methods sections associated with 
figures 3-5, S4 and S7, helped to edit all other sections of the manuscript, and assisted in addressing reviewers’ 
comments for resubmission. 
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(BG)-blood agar and correlates with BvgAS activity. The Bvg+ phase is characterized by 
expression of all currently known protein virulence factor-encoding genes (referred to 
collectively as vags) and lack of expression of BvgAS-repressed genes (called vrgs), which 
includes those encoding flagella in B. bronchiseptica. The Bvg– phase occurs when the bacteria 
are grown at ≤26°C or when millimolar concentrations of MgSO4 or nicotinic acid are added to 
the growth medium (referred to as ‘modulating conditions’). The Bvg– phase is characterized by 
expression of vrg loci and lack of expression of vags. The Bvg-intermediate (Bvgi) phase occurs 
at intermediate temperatures or in the presence of low concentrations of MgSO4 or nicotinic acid 
(9). It is characterized by expression of vags that contain high affinity BvgA binding sites at their 
promoters (such as fhaB, encoding FHA, fimBCD, encoding the FIM biogenesis proteins, and 
bvgAS itself), lack of expression of vags with low-affinity BvgA binding sites (such as 
cyaABDE, encoding ACT and ptxA-E, encoding pertussis toxin), lack of expression of vrgs, and 
maximal expression of bipA, which encodes an outer membrane protein of unknown function (9-
11). Although BvgAS activity is altered by temperature, MgSO4 and nicotinic acid in vitro, the 
true signals it senses in nature are unknown. 
B. pertussis and B. bronchiseptica strains containing loss-of-function mutations in bvgAS 
are avirulent, while strains containing mutations that render BvgAS active even under 
modulating conditions in vitro are indistinguishable from wild-type bacteria in their ability to 
cause respiratory tract infections (12-14). Characterization of antibody responses following 
infection and analyses using recombination-based reporters of gene expression indicate that 
modulation to the Bvg– phase does not occur during infection (12, 15, 16). Studies with strains 
that produce Bvg– phase factors ectopically in the Bvg+ phase have demonstrated the importance 
of BvgAS-mediated repression of gene expression in vivo (14, 17). Taken together, these results 
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have been interpreted to indicate that the Bvg+ phase is both necessary and sufficient for the 
development of respiratory infection by Bordetella. Moreover, these data, together with the fact 
that the phenotypic profile of wild-type bacteria grown at 37°C in SS medium or on BG agar 
(Bvg+ phase conditions) is identical to that of mutants containing bvgS mutations that render 
BvgS insensitive to modulating conditions, have led to the conclusion that these in vitro growth 
conditions mimic, at least to some extent, those experienced by the bacteria in the respiratory 
tract. 
In a survey of putative two component regulatory systems in B. bronchiseptica, we 
discovered a gene (BB0264) predicted to encode an NtrY-like sensor kinase that is essential for 
B. bronchiseptica to colonize the trachea of rats following low-dose, low-volume intranasal 
inoculation and to persist in the lungs of mice following high-dose, large-volume intranasal 
inoculation (18). We named BB0264 plrS, for persistence in the lower respiratory tract sensor. 
Subsequently, Hester et al. reported the identification of a CO2 responsive regulon in Bordetella. 
They hypothesized the existence of a CO2 responsive regulator and suggested that increased CO2 
may be sensed by the bacteria as a cue indicating their localization in the lower respiratory tract 
(LRT) (19). Here, we show that plrS is required for increased virulence factor production in 
response to CO2, and that plrS is required for BvgAS to be fully active in the LRT. We also show 
that plrS is required for persistence in the LRT even when BvgAS is constitutively active, 
indicating that although BvgAS is necessary in vivo, it is not sufficient. Moreover, our data 
suggest the existence of genes that are expressed only in the LRT that encode previously 




PlrS is required for enhanced BvgAS-dependent virulence-associated phenotypes in 
response to elevated CO2 concentrations  
BvgAS-regulated virulence-associated phenotypes include adherence to epithelial cells 
and macrophages, which is mediated by FHA (20, 21), hemolysis on blood-containing agar, 
which is mediated by ACT (22), and toxicity to various eukaryotic cell types in culture, which is 
mediated by the T3SS (23). All of these phenotypes were enhanced when wild-type (WT) B. 
bronchiseptica was grown at 37°C in 5% CO2 compared to growth at 37°C in ambient air (Fig. 
2.1, Fig. 2.S1, and (19)). These virulence-associated phenotypes did not increase in response to 
5% CO2 in the ∆plrS mutant, indicating that PlrS is required for this effect. The effect was not 
due to acidification of the growth medium because acidification alone, without increased CO2, 
did not result in increased adherence (Fig. 2.S2). These results suggest the possibility of a 
functional interaction between PlrS and BvgAS.  
PlrS likely affects BvgAS-dependent phenotypes via PlrR 
A putative response regulator, which we are naming PlrR, is encoded immediately 3’ to 
plrS. Attempts to disrupt or delete plrR (BB0265) were unsuccessful, suggesting plrR is essential 
for cell viability under the growth conditions tested.  As an alternate approach to determine if 
PlrS and PlrR function as a cognate TCS, we delivered a plrR allele (plrRD52E) encoding a PlrR 
protein in which the predicted site of phosphorylation, Asp52, was replaced with Glu, a predicted 
phosphomimetic (24), to the attTn7 site in WT, ∆plrS, and ∆bvgS (which harbors a deletion in 
bvgS) B. bronchiseptica. When grown in 5% CO2, the level of adherence of the ∆plrS strain 
expressing plrRD52E to L2 cells was as high as that of WT B. bronchiseptica (and WT expressing 
plrRD52E), demonstrating that the plrRD52E allele could complement a ∆plrS mutation and, 
therefore, that PlrS likely affects BvgAS-dependent virulence-associated phenotypes via PlrR 
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(Fig. 2.2). Increased adherence in the WT and ∆plrS strains expressing plrRD52E in bacteria 
grown in ambient air is also consistent with the D52E substitution functioning as a 
phosphomimetic, rendering PlrR constitutively active (Fig. 2.2). Lack of adherence by the ∆bvgS 
strain with and without the plrRD52E allele in the presence or absence of 5% CO2 confirms that 
bvgS is required for adherence to host cells and that PlrRD52E does not induce a BvgAS-
independent adherence activity (Fig. 2.2). These data provide evidence (but do not prove) that 
PlrS and PlrR function as a canonical TCS, and that increased adherence in response to CO2 is 
mediated by PlrS via PlrR. However, these data do not rule out the possibility that BvgA and 
PlrR interact synergistically to affect expression of some genes or that PlrS directly interacts with 
BvgS while also affecting the phosphorylation state of PlrR. 
Positive autoregulation of the bvgAS operon is well-documented (25-28). Nonetheless, to 
determine if PlrS affects BvgAS activity by controlling bvgAS transcription, we introduced a 
PbvgA-gfp transcriptional reporter into the attTn7 site of WT and ∆plrS B. bronchiseptica and 
measured GFP activity in bacteria grown at 37°C with and without 5% CO2. Under all conditions 
tested, the levels of GFP, and therefore the expression of bvgAS, was not significantly different 
between WT and the ∆plrS strains (Fig. 2.S3). GFP levels in the ∆bvgS strain reflect activity 
from the bvgA P2 promoter, which is expressed at a low level under Bvg– phase conditions 
(providing the cell with a low amount of BvgAS so that it can respond, via positive 
autoregulation, when Bvg+ phase conditions are encountered) (29). This low level expression of 
PbvgA was not affected by the ∆plrS mutation. Together, these data suggest that PlrS, via PlrR, 
exerts its effects on BvgAS activity post-transcriptionally.  
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B. bronchiseptica lacking plrS modulate to the Bvg– phase within the lower respiratory tract 
Based on the functional link between PlrS and BvgAS (Fig. 2.1) and the similarly rapid 
clearance of B. bronchiseptica ∆plrS and ∆bvgS mutants from the LRT of mice (13, 18), we 
hypothesized that PlrS may influence BvgAS activity within the host. To test this hypothesis, we 
used two reporter systems developed in our lab. pGFLIP contains a recombinase-based reporter 
system, similar to RIVET (15). Expression of flp, encoding FLP recombinase, results in excision 
of gfp and nptII (encoding kanamycin resistance, Kmr) genes located between FLP recombinase 
target (FRT) sites and conversion of the bacteria from GFP+ and Kmr to GFP– and Kms. In 
pGFLIP-flaA, the Bvg– phase-specific PflaA promoter is located 5’ to flp and conversion to GFP
– 
(and Kms) indicates that the bacteria have expressed the Bvg– phase at some point during the 
experiment.  
By contrast with pGFLIP, which reports on the history of the bacteria, the pBAM plasmid 
reports on the status of the bacteria at the time of plating (29). The pBAM plasmid integrates 
within the bvgAS promoter region and causes the P2 promoter to be expressed at a lower-than-
normal level such that, when bacteria are growing under Bvg– phase conditions, the amount of 
BvgAS in a small proportion of cells in the population (~5%) is below the threshold required for 
positive autoregulation, “trapping” these cells in the Bvg– phase (29). When WT B. 
bronchiseptica containing the pBAM plasmid are grown under Bvg– phase conditions and then 
plated onto BG-blood agar and incubated at 37°C (Bvg+ phase conditions), the “trapped” bacteria 
yield colonies that are larger, flatter, and less hemolytic than colonies formed by Bvg+ phase 
bacteria because these colonies contain ~5% phenotypically Bvg– phase bacteria (as the colony 
grows, ~95% of the daughter cells produce enough BvgAS to convert to the Bvg+ phase, while 
~5% remain phenotypically Bvg– phase). We previously referred to these colonies, which are 
easily scored by simple visual inspection, as large colony variants (LCVs) (29). However, 
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because these colonies result from phenotypic bistability and not a genetic change, it is more 
appropriate to refer to them as large colony phenotypes (LCPs), which we will do henceforth. 
While all LCPs result from a founder bacterium that was Bvg– phase at the time of plating, ~95% 
of bacteria that contain pBAM and are Bvg– phase at the time of plating form typical Bvg+ 
phase-appearing (non-LCP) colonies (29). Hence, although the presence of LCPs indicates that 
bacteria have modulated to the Bvg– phase, it vastly underestimates the number of bacteria that 
are Bvg– phase at the time of plating. 
 When grown at 37°C without addition of MgSO4 to the medium (Bvg
+ phase conditions), 
wild-type and ∆plrS strains containing both reporter systems maintained GFP fluorescence and 
no LCPs formed (Fig. 2.S4A and 2.S4B), indicating that neither strain modulated to the Bvg– 
phase. When switched from Bvg+ phase growth conditions to Bvg– phase growth conditions, both 
strains lost GFP fluorescence and a small proportion of LCPs formed after 24 hours (Fig. 2.S4A 
and 2.S4B).  Both reporters, therefore, can accurately report that the bacteria modulated to the 
Bvg– phase and ∆plrS mutants modulate to a similar extent as wild-type bacteria when grown in 
vitro.  
Following intranasal inoculation of BALB/cJ mice, the numbers of colony forming units 
(cfu) recovered from the nasal cavities and lungs of wild-type and ΔplrS strains containing the 
reporters were similar to cfu recovered of the parental strains (without reporters), indicating that 
the reporters do not influence virulence (Fig. 2.3A).  The proportion of GFP– and LCP cfu 
recovered from the nasal cavities was extremely low for both strains, indicating that the bacteria 
did not modulate to the Bvg– phase at this site (Fig. 2.3B and 2.3C). The proportion of GFP– and 
LCP cfu recovered from the lungs of mice inoculated with wild-type bacteria was also extremely 
low. By contrast, 40-80% of the cfu recovered from the lungs of mice inoculated with the ∆plrS 
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strain had lost GFP fluorescence and 10-80% formed LCPs by day 1 post-inoculation (Fig. 2.3B 
and 2.3C), indicating that a majority of these bacteria had modulated to the Bvg– phase and that a 
majority of these bacteria were in the Bvg– phase at the time of recovery from the lungs. These 
findings demonstrate that in strains lacking plrS, the BvgAS phosphorelay fails to remain active 
specifically within the LRT. Moreover, the fact that 10-80% of the bacteria recovered from the 
lungs formed LCPs (i.e., much more than 5%) indicates that the physiology of ∆plrS bacteria in 
the LRT is substantially different from the physiology of ∆plrS bacteria that have modulated to 
the Bvg– phase in vitro by chemical modulators such as MgSO4 (see discussion). 
B. bronchiseptica lacking plrS fail to activate BvgAS within the lower respiratory tract 
To determine if BvgAS can transition from an inactive (Bvg– phase) to an active (Bvg+ 
phase) state in the absence of PlrS activity within the LRT, we inoculated mice with wild-type 
and ∆plrS mutants containing a pGFLIP reporter in which the Bvg+ phase-specific ptxA promoter 
from B. pertussis was cloned 5’ to flp. Both wild-type and ∆plrS strains activated the ptxA 
promoter when switched from Bvg– phase to Bvg+ phase growth conditions in vitro (Fig. 2.S5). 
Similar to what has been shown in B. bronchiseptica and B. pertussis previously (15, 16), 100% 
of the bacteria recovered from both the nasal cavity and the lungs of mice inoculated with Bvg– 
phase wild-type bacteria activated PptxA and therefore transitioned to Bvg
+ phase within 24 hours 
post-inoculation (Fig. 2.3D and 2.3E). By contrast, although all of the cfu recovered from the 
nasal cavities of mice inoculated with the ∆plrS strain were GFP– by 24 hours post-inoculation, 
only ~80% of those recovered from the lungs were GFP– (Fig. 2.3D and 2.3E). While, based on 
this reporter, only a seemingly small proportion of the ∆plrS mutants failed to switch to the Bvg+ 
phase in vivo, it is important to note that the numbers of cfu of the ∆plrS mutant recovered from 
the lungs at days 1 and 3 post-inoculation were ~0.5 and 2 logs lower than the numbers initially 
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present (day 0). It is impossible to determine if the bacteria cleared from the lungs at these time 
points had lost GFP. However, if they remained GFP+ (indicating that they did not switch to the 
Bvg+ phase) then the proportion of ∆plrS bacteria that had transitioned to the Bvg+ phase in the 
LRT would in fact be far less than 1%. Together, our data indicate that full activation and 
maintenance of BvgAS activity in the LRT requires PlrS. 
PlrS is required for B. bronchiseptica persistence in the lower respiratory tract, 
independent of its effects on BvgAS activity 
Lack of production of BvgAS-dependent virulence factors could be the reason that plrS 
mutants are cleared rapidly from the LRT. To test this hypothesis, we introduced the bvgS-C3 
mutation, which encodes a BvgS protein that is active even under modulating conditions in vitro 
(12), into the plrS mutant, and compared this ∆plrS-bvgSc strain with the bvgSc mutant in vitro 
and in vivo. Like the bvgSc strain, the ∆plrS-bvgSc strain formed small, domed, hemolytic 
colonies characteristic of the Bvg+ phase on BG-blood agar containing 50 mM MgSO4 (i.e., Bvg
– 
phase conditions), indicating that BvgAS was constitutively active in the absence of plrS in vitro. 
In vivo, the ∆plrS-bvgSc strain colonized and persisted in the nasal cavity similarly to the bvgSc 
and ΔplrS strains (Fig. 2.S6). However, the ∆plrS-bvgSc strain was cleared from the lungs as 
rapidly as the ∆plrS mutant (Fig 2.S6), indicating that the ∆plrS mutation is epistatic to the bvgS-
C3 mutation with regard to persistence in the LRT.  
To investigate BvgAS activity in the ∆plrS-bvgSc strain, we used our pGFLIP-flaA and 
pBAM reporters. None of the bvgSc or ∆plrS-bvgSc colonies containing these reporters were 
GFP– or displayed the LCP phenotype after growth in medium containing 50 mM MgSO4 (Fig. 
2.S7), indicating their insensitivity to modulating conditions in vitro. Numbers of cfu of each 
strain recovered from the nasal cavities and lungs of BALB/cJ mice were similar to those of the 
strains lacking the pGFLIP-flaA and pBAM reporters (Fig. 2.4A). Additionally, very few, if any, 
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GFP– or LCP colonies were recovered from the nasal cavity for any strain, indicating that no 
bacteria had modulated to the Bvg– phase in the nasal cavity (Fig. 2.4B and 2.4C). As expected, a 
significant proportion of GFP– colonies and LCPs were recovered from the lungs of mice 
inoculated with the ∆plrS mutant on days 1 and 3, consistent with our previous results (Fig. 2.4B 
and 2.4C). By contrast, no GFP– or LCP colonies were recovered from the lungs of mice 
inoculated with the bvgSc or ∆plrS-bvgSc mutants (Fig. 2.4B and 2.4C), indicating that neither 
strain modulated to the Bvg– phase in the LRT.  Therefore, modulation to the Bvg– phase and 
lack of BvgAS-activated virulence factors is not the only reason that ∆plrS mutants fail to persist 
in the LRT. These data indicate that PlrS is required for bacterial persistence in the LRT even 
when BvgAS remains active, likely because PlrR (presumably phosphorylated PlrR, PlrR~P) 
activates expression of one or more genes encoding proteins that are required in this environment 
or because PlrR~P represses expression of one or more genes that encode proteins that are 
detrimental to survival in this environment.  
PlrS is required for survival and persistence of B. pertussis in the lower respiratory tract 
 The plrSR locus is highly conserved (≥99% identical) among all strains of the classic 
bordetellae (B. pertussis, B. bronchiseptica and B. parapertussis). We constructed a derivative of 
B. pertussis strain BP536 with a large in-frame deletion mutation in plrS and compared it with 
wild-type BP536 in BALB/cJ mice. Both strains colonized the nasal cavity at similar levels, and 
were cleared from this site by day 3 post-inoculation (Fig. 2.5). However, while approximately 
103 cfu of BP536 were recovered from the lungs on days 1 and 3 post inoculation, significantly 
fewer BP536ΔplrS cfu were recovered from this site at these time points (Fig. 2.5). These data 
indicate that similar to B. bronchiseptica, plrS is required for the survival and persistence of B. 
pertussis specifically in the lower respiratory tract.    
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Discussion 
 BvgAS has been considered the master virulence regulator in Bordetella since its 
identification in 1983 (30) and demonstration of its penetrance by subsequent mutagenesis and 
genome-wide analyses (8, 31, 32). Our new data indicate, however, that in the LRT, BvgAS 
activity depends on PlrS, likely via the activity of PlrR. Moreover, PlrS(R) is required for 
bacterial survival in the LRT even when BvgS is rendered constitutively active, strongly 
suggesting that one or more PlrSR-dependent, BvgAS-independent genes (or genes that require 
both PlrSR and BvgAS) is required for bacterial survival at this site. PlrS(R) is therefore at least 
as important for Bordetella virulence as BvgAS. 
Why is PlrS(R) required for bacterial persistence in the LRT? PlrSR belongs to the NtYX 
family of TCS. NtrY family proteins, including PlrS, are predicted to contain three 
transmembrane domains at their N-termini, followed by a periplasmically-located PhoP-DcuS-
CitA (PDC) domain, another transmembrane domain, then cytoplasmically-located HAMP, Per-
Arnt-Sim (PAS) and HisKA-type histidine kinase domains (Fig 2.6). NtrY of Brucella abortus 
has been shown to bind heme via its PAS domain and to function as a redox sensor, becoming 
active as a kinase in response to anaerobiosis (33). NtrX family response regulators contain N-
terminal receiver and C-terminal DNA binding domains.  In Neisseria gonorrhoeae and 
Rhodobacter capsulatus, the ntrX genes are required for induction of high-affinity cytochrome 
oxidases, which are required for bacterial growth under low oxygen conditions (34). Our data 
indicate that PlrS is required specifically in the LRT, an environment that is low in oxygen and 
high in CO2. Although we have been unable to delete plrR in vitro, our experiments using 
PlrRD52E indicate that PlrS affects BvgAS-dependent phenotypes in vitro via PlrR (providing 
evidence that PlrS and PlrR function as a TCS). It seems likely that PlrS functions through PlrR 
in vivo as well. By analogy with the few other NtrYX family members that have been studied so 
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far, we hypothesize that PlrS senses low oxygen (and perhaps increased CO2) in the LRT, 
phosphorylates PlrR, and that PlrR~P activates expression of one or more of the high-affinity 
cytochrome oxidase-encoding loci present in B. bronchiseptica (and B. pertussis) (35), allowing 
the bacteria to respire in this environment (Fig. 2.6). We note, however, that NtrY family 
members, including PlrS, contain HisKA-type DHp domains with ExxN motifs that suggest that 
these proteins possess both kinase and phosphatase activities (36-38). Although our data suggest 
that PlrS may function to phosphorylate PlrR in vitro, especially in 5% CO2, the contributions of 
its predicted kinase and phosphatase activities in vivo cannot be predicted from our current data. 
We are currently investigating the role of PlrS activities in vitro and in vivo. 
Why is PlrS(R) required for BvgAS activity in the LRT? Positive autoregulation by 
BvgAS has been well-characterized (25-28, 39) and we showed here that bvgAS expression in 
both ambient air and 5% CO2 is not dependent on plrS. Our experiments with the bvgS
c mutant 
further indicate that bvgAS expression is not dependent on PlrS(R) in vivo because BvgAS in the 
∆plrS-bvgSc strain, which contains a single nucleotide substitution in bvgS, rendering the BvgS 
protein constitutively active, was active in the LRT. If bvgAS transcription required PlrSR, the 
∆plrS mutation would be epistatic to the bvgS-C3 mutation. Our data therefore rule out the 
possibility that PlrS(R) controls BvgAS activity by controlling bvgAS transcription. We 
hypothesize that instead, PlrSR controls expression of one or more genes that encode proteins 
required for BvgS activity specifically in the LRT. BvgS contains three predicted signal-sensing 
domains; two periplasmically-located venus fly-trap (VFT) domains and a cytoplasmically-
located PAS domain (40, 41). While the VFT domains appear to convert BvgS into a 
phosphatase that dephosphorylates BvgA in response to modulating conditions (i.e., MgSO4 or 
nicotinic acid) (42-44), a role for the PAS domain has not been established. However, 
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biochemical analyses using the cytoplasmic portion of BvgS suggested that the redox state of 
ubiquinone could affect BvgS kinase activity (45). PlrSR-dependent production of high-affinity 
cytochrome oxidases would both allow electron transport-coupled oxidative phosphorylation to 
occur in the LRT, which is required for both ATP production (and hence cell viability), and 
prevent the accumulation of reduced ubiquinone, which could inactivate BvgS. This model is 
consistent with that proposed for the ArcB protein of Escherichia coli, which is activated by low 
oxygen conditions (46, 47). If true, this model would predict that a role for the PAS domain in 
sensing signals in vitro may have been missed because the activity of low-affinity (high 
efficiency) cytochrome oxidases present under all of the conditions tested would keep reduced 
ubiquinone levels at a minimum. These low-affinity cytochrome oxidases are also likely present 
and sufficient for respiration in the URT, making BvgS activity and bacterial survival at this site 
independent of PlrS.   
Why was the proportion of LCPs recovered from the lungs of mice inoculated with the 
∆plrS strain so much higher than the proportion obtained after switching the bacteria from Bvg– 
phase conditions to Bvg+ phase conditions in vitro? Our previous studies showed that the reason 
that ~5% of bacteria containing the pBAM plasmid integrated at the bvgAS promoter region form 
LCPs when shifted from Bvg– phase conditions to Bvg+ phase conditions in vitro, is that activity 
of the P2 promoter in this strain is decreased such that ~5% of the bacteria have BvgAS levels 
below the threshold required to respond to Bvg+ phase conditions when they are encountered. It 
appeared, therefore, that the maximum proportion of LCPs that would form from a population of 
pBAM-containing bacteria in which 100% of the bacteria had modulated to the Bvg– phase was 
about 5%. We were surprised, therefore, to find that the proportion of LCPs formed after recovery 
of the ∆plrS mutant from the lungs of mice was up to 80%. Given that the activity of the P2 
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promoter is already extremely low, it seems unlikely that P2 promoter activity in the ∆plrS mutant 
is substantially lower in the LRT than under Bvg– phase conditions in vitro. A more likely 
possibility is that the physiology of the ∆plrS mutant in the LRT is substantially different from the 
physiology of the ∆plrS mutant growing under Bvg– phase conditions in vitro (and from WT 
bacteria in the LRT, which do not modulate to the Bvg– phase), and that this altered physiology 
prevents or delays BvgS from reactivating upon exposure to Bvg+ phase conditions in vitro. If 
PlrS(R) controls expression of cytochrome oxidases in the LRT, and if BvgS is sensitive to the 
redox state of ubiquinone, then BvgS would be inactive in a plrS mutant in the LRT and would not 
become active again until cytochrome oxidase activity reached levels sufficient to reoxidize 
ubiquinone pools, which, in the case of a plrS mutant, could require expression of genes encoding 
low-affinity cytochrome oxidases, translation of proteins, and assembly of enzymatic complexes 
in the membrane after the bacteria are shifted to Bvg+ phase conditions in ambient air. This delay 
could account for the substantially higher proportions of LCPs formed by the plrS mutant 
recovered from the LRT compared to the proportion formed after growth in vitro. 
 Disproving the long-held paradigm that the Bvg+ phase is sufficient for respiratory 
infection and evidence that virulence factors that require PlrS(R) independently of (or 
codependently with) BvgAS exist are important results from a translational medicine 
perspective. B. bronchiseptica and B. pertussis are sufficiently closely related to be considered 
members of the same species (35), and several vags have been shown to be functionally 
interchangeable (48-51).  As in B. bronchiseptica, a B. pertussis plrS mutant was defective in 
persistence in the LRT. Our model for the role of PlrSR during infection based on studies with B. 
bronchiseptica is therefore likely to apply to B. pertussis as well. In addition to mounting 
evidence that acellular and whole cell vaccines provide suboptimal protection that is less durable 
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than that induced by infection with B. pertussis, recent data from studies with baboons indicate 
that although both vaccines protect against disease, neither protects against colonization (52). 
Moreover, baboons vaccinated with an acellular vaccine and then challenged with B. pertussis 
were able to transmit the disease to naïve animals, even though they exhibited no signs of illness 
(52). The fact that infection induces a mixed Th1/Th17-type immune response and acellular 
vaccines induce a strong Th2-type immune response (4, 53-56) suggests that reformulation of 
acellular vaccines with adjuvants to induce a Th1/Th17 response is a reasonable approach to 
controlling the reemergence of pertussis. However, the phenomenon of epitope-linked 
suppression would likely render such vaccines ineffective in individuals previously vaccinated 
with acellular vaccines and perhaps also in those vaccinated with whole cell vaccines, which are 
prepared from in vitro grown bacteria. Inclusion of antigens not present in previous vaccines 
would avoid this problem. The existence of virulence factors that are produced only in the host 
during infection, as suggested by our data, is significant from this translational medicine 
perspective. Antigens that are produced only during infection could also be important 
diagnostically as a means to distinguish individuals who have been vaccinated from those who 
have been infected. Finally, PlrSR itself, and factors it controls, may be exploitable as 
therapeutic targets. 
Materials and Methods   
Growth media and bacterial strains 
Escherichia coli was grown in lysogeny broth (LB) or on LB agar at 37°C. Wild-type 
Bordetella bronchiseptica RB50 and Bordetella pertussis BP536 (and their mutant derivatives) 
were grown at 37°C on Bordet Gengou (BG) agar (Becton Dickinson Microbiology Systems) 
supplemented with 7.5% or 15% defibrinated sheep blood, respectively (Hardy Diagnostics, 
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Santa Maria, CA., Colorado Serum Co., Denver, CO and Hemostat, Dixon, CA) or in Stainer-
Scholte (SS) broth with SS supplement; 100 mg/ml (2,6-O-dimethyl) cyclodextrin (Heptakis) 
was added to B. pertussis cultures.  When necessary, media were supplemented with 
streptomycin (Sm) (20 μg/ml), gentamicin (Gm) (30 μg/ml), kanamycin (Km) (E. coli- 50 μg/ml 
or B. bronchiseptica- 125 μg/ml), or diaminopimelic acid (DAP) (300 μg/ml). To visualize 
hemolysis on solid media, bacteria were grown in ambient or 5% CO2 conditions for 2.5 days on 
BG blood agar plates and colonies were photographed with a Canon EOS 40D digital camera in 
the presence of both overhead lighting and backlighting.  
Construction of cloning plasmids and bacterial strains 
Descriptions of each strain are given in Table S1.  The strain ΔplrS-bvgSc, containing the 
bvgS-R570H mutation and an in-frame deletion mutation in the plrS gene, was created using 
plasmid pMD11 (18) in an allelic exchange method that has been previously described (50). A B. 
bronchiseptica strain with a disruption in the bscN gene (BB1628, which encodes the ATPase for 
the Type III secretion system), was created by cloning a 0.34 kb internal portion of bscN into the 
suicide vector pEG7, producing plasmid pSJ43, which was then integrated into the native bscN 
locus in the chromosome.  The disruption was confirmed by PCR.   
A B. pertussis 536 strain containing an in-frame deletion in the plrS (BP0571) gene was 
constructed by a pSS4245-based allelic exchange method such that all but the first eight and last 
two codons of BP0571 were deleted. Two 600-basepair DNA fragments flanking the region to be 
deleted were generated by PCR, and to facilitate the allelic exchange, a spectinomycin-resistant 
(SpcR) synthetic DNA cassette was inserted between the two PCR products to generate plasmid 
pQC2053. This plasmid was conjugated into BP536, to generate a ∆BP0571::spc strain, QC3729. 
To replace the SpcR-marked BP0571 deletion with an unmarked, in-frame deletion, plasmid 
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pQC2027, which had been constructed by removing the SpcR DNA cassette from pQC2053, was 
conjugated into strain QC3729, and an in-frame BP0571 deletion that had replaced the 
BP0571::spc allele was identified by screening exconjugates for a spectinomycin-sensitive 
phenotype following allelic exchange.  One of these was chosen as BP536ΔplrS and confirmed 
by PCR. 
Derivatives of B. bronchiseptica that contained the pGFLIP-PflaA and pGFLIP-Pptx 
reporters were constructed using methods previously described (15).  The pBam reporter system 
was delivered to the bacterial chromosome via homologous recombination (29).    
In vitro adherence assays  
Bacterial adherence to rat lung epithelial (L2) cells was evaluated as described (21, 48). 
Bacteria were cultured in either ambient air or 5% CO2 at 37° to an OD600 of approximately 1.0.  
Bacteria were added to a monolayer of L2 cells (~80% confluency) at a multiplicity of infection 
(MOI) of 150. Adherence was visualized by Giemsa staining and light microscopy at 1000X 
magnification using a Zeiss Axiostar microscope, and quantified by counting the number of 
adherent bacteria and total L2 cells in at least 4 microscopic fields.   
Macrophage cytotoxicity assays  
J774 macrophage-like cells were grown to ~60% confluency (~1.5 x 104 cells/well) in a 
96-well microtiter dish. Bacteria were cultured in either ambient air or 5% CO2 to an OD600 of 
~1.0, and were then added to J774 cells at an MOI of 150. The plate was spun at 1200 x g and 
then allowed to incubate in a tissue culture incubator for 3 hours. Macrophage cytotoxicity was 
quantified by measuring lactate dehydrogenase (LDH) release using Promega’s Cytotox96 Non-
reactive Cytotoxicity Assay kit and a MultiskanEX plate reader (ThermoFisher Scientific, 
Waltham, MA) according to the manufacturer's instructions.   
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Bacterial adherence to J774 cells and in response to being cultured in media with decreased 
pH 
Adherence to J774A.1 (J774) murine macrophage-like cells was performed essentially as 
described (48). In this study, bacteria were cultured in ambient or 5% CO2 conditions to an 
OD600 of approximately 1.0 and added to J774 cells (at approximately 60% confluency) at an 
MOI of 200. Adherent bacteria were labeled using sera that had been collected from an RB50-
infected rat, and then recognized with an anti-rat Cy3-conjugated secondary antibody. Adherence 
was quantified via fluorescence microscopy by counting the number of adherent bacteria and 
total J774 cells in at least 4 independent microscopic fields at 400X magnification. To determine 
the role of pH in bacterial adherence to L2 cells, the pH of Stainer-Scholte media was adjusted to 
6.8, filter sterilized, and used to culture RB50 under ambient conditions. Adherence to L2 cells 
was performed as described in Materials and Methods.  
Evaluation of B. bronchiseptica bvgAS transcription in vitro 
A transcriptional PbvgA-gfp reporter was created by PCR-amplifying the bvgAS promoter 
(PbvgA, 350 bp upstream of bvgA) using the forward primer 5’-
GATCCCGGGGTAGTCTGGATAA-3’ and the reverse primer 5’-
GATAAGCTTGATAAGAAGAAT-3’. The PCR product was digested and cloned into the XmaI 
and HindIII restriction sites of the miniTn7-kan-gfp plasmid (57). The resulting pUC-PbvgA-gfp 
plasmid was mated into WT, ∆plrS, ∆bvgS, and ∆bvgS∆plrS along with pTNS3, which encodes 
the transposase, allowing for the reporter to integrate into the attTn7 site of the B. bronchiseptica 
chromosome. The resulting strains were confirmed by PCR. 
To determine the level of transcription at the bvgAS promoter, reporter strains were 
grown on BG agar with appropriate antibiotics until colonies formed. Colonies were resuspended 
in 1X PBS, and this suspension was used to inoculate duplicate tubes grown overnight for ~18 
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hrs in Stainer-Scholte media with streptomycin and kanamycin either at 37°C on a roller or at 
37°C shaking in the presence of 5% CO2. One hundred microliters of each culture were 
transferred to a well of a 96-well plate, and the OD600 and GFP (excitation A485, emission 
A535) were measured on a Perkin Elmer Victor3 1420 Multilabel plate reader, and GFP 
expression was normalized to OD600. The experiment was performed on two separate days in 
duplicate, and values were averaged across all replicates.  
Evaluation of B. bronchiseptica promoter activity in vitro 
Strains containing pGFLIP-PptxA were grown overnight in the presence of 50 mM 
MgSO4. Cells were washed twice in 1x PBS with 50 mM MgSO4 to prevent the premature 
transition to the Bvg+ phase and were then inoculated into fresh SS medium without MgSO4 at a 
concentration of 1 x 109 cfu/ml, and incubated at 37°C for 8 h. At each time point, an aliquot of 
cells was removed, diluted with 1x PBS containing 50 mM MgSO4, and plated on BG-blood agar 
also containing 50 mM MgSO4. Plates were incubated for 48 h at 37°C, and total cfu were 
enumerated. The percent GFP negative colonies was determined for each plate as described in 
Materials and Methods.  
Strains containing pGFLIP-PflaA and pBam were grown overnight in SS medium with and 
without 50 mM MgSO4. After incubation at 37°C for 24 h, an aliquot of cells from each 
experimental condition was diluted with 1x PBS and plated on BG-blood agar. Plates were 
incubated for 48 h at 37°C, and total cfu were enumerated. The percent GFP negative colonies 
was determined for each plate as described in Materials and Methods. 
Bacterial colonization of the mouse respiratory tract 
Six-week-old female BALB/cJ mice from Jackson Laboratories (Bar Harbor, ME) were 
inoculated intranasally with 7.5 x 104 cfu B. bronchiseptica or 1.0 x 105 CFU B. pertussis in 
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50μL of phosphate-buffered saline (PBS). For all time points, right lung lobes and nasal cavities 
were harvested, tissues were homogenized, and the number of cfu was determined by plating 
dilutions of tissue homogenates on BG blood agar.  
Evaluation of B. bronchiseptica phenotypic phase transition in vivo 
Six-week-old female BALB/cJ mice (Jackson Laboratories, Bar Harbor, ME) were 
inoculated intranasally with 7.5 x 104 cfu of B. bronchiseptica pGFLIP strains in 50 μL of PBS.  
For experiments utilizing the pGFLIP-PptxA reporter, bacteria were cultured in media containing 
50mM MgSO4 to maintain the bacteria in the Bvg
– phase prior to mouse inoculation (15).  For 
infections using the pGFLIP-PflaA or pBam systems, bacteria were cultured at 37° in media 
without the addition of MgSO4 to maintain bacteria in the Bvg
+ phase prior to mouse inoculation 
(15, 29).  On days 0, 1, and 3 post-inoculation, right lungs were harvested, homogenized in PBS, 
and plated in duplicate on BG-blood agar. For strains containing the pGFLIP-PptxA system, 
homogenization, dilution, and plating were carried out in the presence of 50mM MgSO4. The 
percent GFP– colonies and percent LCP colonies were calculated by determining the ratio of 
GFP– or LCP colonies to the total number of colonies isolated.   
Ethics statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. Our protocol 
was approved by the University of North Carolina IACUC (Protocol ID: 13-238). All animals 
were properly anesthetized for inoculations, monitored regularly, and euthanized when 
moribund. Efforts were made to minimize suffering.   
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Statistical analysis 
Statistical analysis was performed using Prism 6.0 software from GraphPad Software, 
Inc. Statistical significance was determined using unpaired Student’s t test. Figures were 
generated using Adobe Illustrator CS6 (Adobe Systems, Inc.).  
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Figures and Tables 
 
 
Figure 2.1.  PlrS is required for Bvg-dependent phenotypes in 5% CO2 growth conditions.  
(A) Bacterial adherence to L2 lung epithelial cells.  Wild-type (WT) and ΔplrS bacteria were 
cultured in ambient (37°C) or 5% CO2 (37°C + 5% CO2) conditions before inoculation at an 
MOI of 150 onto an L2 monolayer. The number of adherent bacteria per L2 cell was enumerated 
by determining the average number of bacteria and L2 cells visible from four visual fields of the 
microscope.  Error bars represent standard deviation of the mean (SD). (B) Hemolysis on blood 
agar media produced from WT, ΔplrS, and RB515 (an ACT null mutant) colonies under the 
indicated growth condition. (C) Cytotoxicity of macrophage-like J774 cells induced by WT, 
ΔplrS, ΔbscN (containing an insertional disruption in the gene encoding the ATPase of the Type 
III Secretion System), and ΔbvgS (containing a deletion in bvgS) strains, following bacterial 
growth under the indicated condition. Percent cytotoxicity was calculated as the ratio of lysed 
J774 cells resulting from bacterial inoculation to fully lysed J774 cells, and error bars represent 
SD.  Statistical significance (t test) is indicated with * (P < 0.05), ** (P < 0.01), *** (P < 0.001) 
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Figure 2.2. Overexpression of a phosphomimetic plrR allele rescues the ΔplrS L2 cell 
adherence defect. (A) L2 lung epithelial cell adherence displayed by wild type (WT), ΔplrS, 
WT-plrRD52E (a strain isogenic to WT that produces PlrR with the phosphomimetic D52E 
substitution), ΔplrS-plrRD52E (ΔplrS that produces PlrR with the phosphomimetic D52E 
substitution), ∆bvgS and ΔbvgS-plrRD52E (ΔbvgS that produces PlrR with the phosphomimetic 
D52E substitution) following bacterial growth under the indicated condition. Error bars represent 








Figure 2.3. Without PlrS, B. bronchiseptica modulates to the Bvg– phase in the lower 
respiratory tract. (A) Colonization of the nasal cavity (top) and right lung (bottom) for wild 
type (WT; filled circles) and ΔplrS (red triangles) on days 0, 1 and 3 post inoculation. Both 
strains contain the plasmid reporters, pGFLIP-PflaA and pBam. Female BALB/cJ mice were 
inoculated with 7.5 x104 cfu via the external nares. Each symbol represents a single animal, with 
the mean colonization depicted as a short horizontal bars. Homogenate from each organ was 
assessed to determine in vivo bacterial modulation shown in graphs B and C. (B) Percentage of 
GFP– bacteria recovered from the nasal cavity and right lung for WT and ΔplrS containing 
pGFLIP-PflaA and pBam. GFP
 negativity indicates bacterial modulation. (C) Percentage of large 
colony phenotype (LCP) producing bacteria recovered from the nasal cavity and right lung for 
WT and ΔplrS containing pGFLIP-PflaA and pBam. LCPs indicate bacteria present in the Bvg
– 
phase when plated. (D) Colonization of the nasal cavity (top) and right lung (bottom) for WT 
(filled circles) and ΔplrS (red triangles) containing the plasmid reporter, pGFLIP-PptxA. 
Homogenate from each organ was assessed to determine BvgAS activation in vivo, shown in 
graph E. (E) Percentage of GFP– bacteria recovered from the nasal cavity (top) and right lung 
(bottom) for WT and ΔplrS containing pGFLIP-PptxA. GFP
 negativity indicates BvgAS 
activation. Statistical significance (t test) is indicated with * (P < 0.05), ** (P < 0.01), *** (P < 




Figure 2.4. PlrS is required for persistence of B. bronchiseptica in the LRT independent of 
BvgAS activity. (A) Colonization of the nasal cavity (top) and right lung (bottom) B. 
bronchiseptica containing constitutively-active BvgS (bvgSc; black squares), ΔplrS (red 
triangles), and ΔplrS-bvgSc (blue squares) on days 0, 1 and 3 post inoculation. All strains contain 
the plasmid reporters, pGFLIP-PflaA and pBam. Female BALB/c mice were inoculated with 7.5 
x104 cfu via the external nares. Each symbol represents a single animal, with the mean 
colonization depicted as a short horizontal bars. Homogenate from each organ was assessed to 
determine in vivo bacterial modulation shown in graphs B and C. (B) Percentage of GFP– 
bacteria recovered from the nasal cavity and right lung for bvgSc, ΔplrS, and ΔplrS-bvgSc 
containing pGFLIP-flaA and pBam. GFP negativity indicates bacterial modulation. (C) 
Percentage of large colony phenotype (LCP) producing bacteria recovered from the nasal cavity 
and right lung for bvgSc, ΔplrS, and ΔplrS-bvgSc containing pGFLIP-PflaA and pBam. LCPs 
indicate bacteria present in the Bvg– phase when plated. Statistical significance (t test) is 






Figure 2.5. PlrS is required for the persistence of Bordetella pertussis in the lower 
respiratory tract. (A) Colonization of the nasal cavity (top) and right lung (bottom) for B. 
pertussis strains BP536 (filled circles) and BP536ΔplrS (red diamonds) on days 0, 1 and 3 post 
inoculation. Female BALB/c mice were inoculated with 1.0 x105 cfu via the external nares. Each 
symbol represents a single animal, with the mean colonization depicted as a short horizontal 














Figure 2.6. PlrSR and BvgAS work in tandem to regulate gene expression required for 
Bordetella persistence in the lower respiratory tract. Model of putative PlrSR and BvgAS 
regulatory networks in Bordetella. The sensor kinase PlrS may be sensitive to CO2 or oxygen 
tension, directly or indirectly, within the lower respiratory tract environment, transmitting a 
signal via autophosphorylation and phosphate transfer to its putative response regulator PlrR. 
PlrSR activates (pags) or represses (prgs), a set of genes independent of BvgAS that are required 
for survival of the bacteria specifically within the LRT. PlrSR may also regulate expression of a 
gene(s) encoding proteins required for sustained activity of BvgAS in the LRT. If BvgS receives 
such a signal the sensor kinase is capable of phospho-relay transmission, activating transcription 














Figure 2.S1. Bacterial adherence to macrophage-like murine J774 cells. Wild-type (WT) and 
ΔplrS strains were cultured under ambient (37°C) or 5% CO2 (37°C + 5% CO2) conditions and 
then inoculated at an MOI of 200 onto a monolayer of J774 cells.  The number of adherent 
bacteria per J774 cell was enumerated by determining the average number of bacteria and J774 
cells visible from four visual fields of the microscope, and error bars represent standard deviation 





Figure 2.S2. Increased adherence of wild-type B. bronchiseptica to L2 lung epithelial cells 
does not result from bacteria responding to lowered pH of the growth media. (A) Wild-type 
(WT) B. bronchiseptica was cultured in Stainer-Scholte (SS) media in ambient (no CO2) or 5% 
CO2 (+CO2) conditions, or in ambient conditions after the media had been adjusted to pH 6.8 
(pH 6.8).  The pH of SS media (7.6) will decrease to 6.8 when media without bacteria is 
incubated under 5% CO2 conditions.  Adherence to L2 cells was enumerated by determining the 
average number of bacteria and L2 cells visible from four visual fields of the microscope, and 
error bars represent standard deviation of the mean. Statistical significance (t test) is indicated 





Figure 2.S3. PlrS does not transcriptionally regulate the expression of the bvgAS in vitro. 
(A) WT, ∆plrS, ∆bvgS, and ∆bvgS∆plrS with the transcriptional reporter PbvgAS-gfp (the bvgAS 
promoter driving expression of gfp) were cultured in Stainer-Scholte media under Bvg+ phase 
growth conditions at 37°C with or without 5% CO2 for ~ 18 hrs with agitation. For each strain, 
OD600 and GFP (excitation A485, emission A535) were measured and GFP expression was 
normalized to OD600. The experiment was performed twice in duplicate. GFP/OD600 values were 





Figure 2.S4. In vitro analysis of wild type and ΔplrS modulation using the plasmid reporters 
pGFLIP-flaA and pBam. Wild type (WT) and ΔplrS containing pGFLIP-flaA and pBam were 
cultured under Bvg+ and Bvg– phase growth conditions (SS broth without and with 50 mM 
MgSO4, respectively) at 37°C for ~18 hrs with agitation and subsequently plated on BG-blood 
solid agar to enumerate the percentage of GFP negative colonies (A) and LCPs (B). GFP 
negativity indicates bacterial modulation and LCPs indicate bacteria present in the Bvg– phase 




Figure 2.S5. In vitro analysis of wild type and ΔplrS phase transition using the plasmid 
reporter pGFLIP-ptxA. (A) Wild-type (WT) and ΔplrS bacteria containing pGFLIP-ptxA were 
cultured under Bvg+ and Bvg– phase growth conditions (SS broth without and with 50mM 
MgSO4, respectively) at 37°C for 8 hrs with agitation. At various time points culture samples 
were taken and subsequently plated on BG-blood solid agar to enumerate the percentage of GFP 





Figure 2.S6. A constitutively-active bvgS mutation does not prevent rapid clearance of a 
ΔplrS strain in the lower respiratory tract. (A) Colonization of the nasal cavity and right lung 
for bvgSc (black squares), ΔplrS (red triangles), and ΔplrS-bvgSc (blue squares) strains on days 0 
and 3 post inoculation. Female BALB/c mice were inoculated with 7.5 x104 cfu via the external 
nares. Each symbol represents a single animal, with the mean colonization depicted as a short 





Figure 2.S7. In vitro modulation of constitutively-active bvgS strains using the plasmid 
reporters pGFLIP-flaA and pBam. The strains bvgSc, ΔplrS, and ΔplrS-bvgSc containing 
pGFLIP-flaA and pBam were cultured under Bvg+ and Bvg– phase growth conditions (SS broth 
without and with 50 mM MgSO4, respectively) at 37°C for ~18 hrs with agitation and 
subsequently plated on BG-blood solid agar to enumerate the percentage of GFP negative 
colonies (A) and LCPs (B). GFP negativity indicates bacterial modulation and LCPs indicate 
bacteria present in the Bvg– phase when plated. Statistical significance (t test) is indicated with * 
(P < 0.05) and ** (P < 0.01). 
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Table 2.S1. Bacterial Strains and Plasmids Used in this Study 
Bacterial Strain or 
Plasmid 
Description Reference 
E.coli Strains   
DH5α Molecular cloning strain 
BRL; 
Gaithersburg, MD 
RHO3 Conjugation strain; Kms Δasd ΔaphA, DAP auxotroph (57) 




WT Wild-type B. bronchiseptica strain RB50; Smr (12) 
ΔplrS 
RB50 containing an in-frame deletion in plrS removing the codons for 
amino acids 5 to 198; Smr 
(18) 
RB515 RB50ΔcyaA (51) 
bvgSC RB50 containing a R570H point mutation in bvgS; Smr (12) 
ΔplrS-bvgSC 
RB50 containing a R570H point mutation in bvgS and a deletion in plrS 
removing the codons for amino acids 5 to 198; Smr 
This Study 
ΔbscN 
RB50::pSJ23; RB50 containing a plasmid insertion mutation in bscN 
(BB1628); Gmr 
This Study 




BP536 Wild-type B. pertussis strain; Smr (58) 
BP536ΔplrS 
B. pertussis strain containing an in-frame deletion in plrS from residues 9 
thru 768; Smr 
This Study 
   
Plasmids   
pMD11 
pSS4245-based allelic exchange vector containing a 0.8-kb DNA fragment 
deleting the codons for amino acids 5 to 198 of plrS 
This study 
pGFLIP-PflaA 
pUC18-based vector with PS12-gfp and nptII flanked by FRT sequences 
and flp recombinase driven by the RB50 flaA promoter; Apr Kmr* 
(15) 
pGFLIP-PptxA 
pUC18-based vector with PS12-gfp and nptII flanked by FRT sequences 
and flp recombinase driven by the BPSM ptxA promoter; Apr, Kmr* 
(15) 
pTNS3 Tn7 transposase expression vector containing tnsABCD; Apr (57) 
pBam 
Plasmid that integrates into the Bordetella chromosome at the bvgAS locus 
and allows for generation of LCPs; Apr, Gmr 
(29) 
pEG7 Suicide plasmid for B. bronchiseptica; Gmr (9) 
pSJ23 
pEG7-based suicide plasmid containing a B. bronchiseptica DNA fragment 
from bscN (BB1628); Gmr 
This Study 
   
* Kmr only under promoter-inactive conditions 
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CHAPTER 3. THE BVGS PAS DOMAIN: AN INDEPENDENT SENSORY 
PERCEPTION MODULE IN THE BORDETELLA BRONCHISEPTICA BVGAS 
PHOSPHORELAY2 
Introduction 
Pertussis, also known as whooping cough, is a severe, highly contagious, reemerging 
respiratory disease (1). It is caused by the bacterium Bordetella pertussis, which infects only 
humans and appears to be capable of surviving only transiently outside the human respiratory 
tract (2). By contrast, the closely related species Bordetella bronchiseptica infects nearly all 
mammals and can survive long periods of time in ex vivo environments, including those with 
scarce nutrients such as filtered pond water and buffered saline (3, 4). Despite these differences, 
B. pertussis and B. bronchiseptica produce a nearly identical set of virulence factors that are 
regulated at the level of transcription by functionally interchangeable BvgAS Two-Component 
Regulatory Systems (TCS) (5). By activating and repressing at least four classes of genes, 
BvgAS controls transition of the bacteria between three different phenotypic phases: the Bvg+ 
phase, which is necessary for virulence in mammals (4), the Bvg– phase, which, in B. 
bronchiseptica, is required for survival under nutrient-limiting conditions (4) and for interactions 
with non-mammalian hosts (6), and the Bvgi phase, which has been hypothesized to be important 
for bacterial transmission (7). 
                                                     
2 M. Ashley Sobran and Peggy A. Cotter. “The BvgS PAS domain: an independent sensory perception module in the 
Bordetella bronchiseptica BvgAS phosphorelay”. Accepted at Journal of Bacteriology. MAS contributed to this 
manuscript by assisting in the design, performance, and analysis of all presented research. MAS compiled and 
formatted all figures and tables, wrote all sections of the manuscript with the assistance of PAC, and addressed all 
reviewer comments with the assistance of PAC.  
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The BvgAS system is composed of an unorthodox sensor kinase, BvgS, and a response 
regulator, BvgA (8). BvgS contains tandem, N-terminal, periplasmic Venus Flytrap (VFT) 
domains, followed by a transmembrane domain, a cytoplasmic Per/Arnt/Sim (PAS) domain, a 
histidine kinase (HK) domain, a receiver (REC) domain, and a C-terminal, histidine 
phosphotransfer (Hpt) domain (Fig. 3.1A). BvgA contains an N-terminal REC domain and a C-
terminal helix-turn-helix (HTH) DNA binding domain. When Bordetella are grown on Bordet-
Gengou (BG) blood agar or in Stainer-Scholte (SS) broth at 37C, BvgS autophosphorylates, 
and, via a His-Asp-His-Asp phosphorelay, trans-phosphorylates BvgA. BvgA~P forms 
homodimers capable of binding DNA and activating or repressing gene transcription (9). Under 
these conditions, BvgA~P levels are high and the bacteria express the Bvg+ phase, which is 
characterized by transcription of all known vir-activated genes (vags), including those encoding 
critical virulence factors (10). When Bordetella are grown at 25°C or at 37°C in the presence of 
millimolar concentrations of nicotinic acid (NA) or magnesium sulfate (MgSO4), BvgA is 
unphosphorylated (11), presumably due to the reversal of the BvgAS phosphorelay, resulting in 
the Bvg– phase. The Bvg– phase is characterized by the expression of genes that are repressed by 
BvgA~P (termed vir-repressed genes (vrgs)) and lack of expression of vags (10). In B. 
bronchiseptica, flagellar regulon genes, including the flagellin-encoding gene flaA, are vrgs (12). 
When Bordetella transition from the Bvg– phase to the Bvg+ phase, or when the bacteria are 
cultured in the presence of low concentrations of NA or MgSO4, BvgA~P levels in the cell are 
low, resulting in the Bvgi phase, which is characterized by repression of the vrgs, maximal 
expression of the intermediate phase gene bipA, and expression of vags with promoters 
containing high affinity BvgA~P binding sites (such as bvgAS itself and fhaB, encoding the 
adhesin filamentous hemagglutinin (FHA)) but not vags with promoters containing low affinity 
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BvgA~P binding sites (such as the ptx operon, which encodes pertussis toxin and its export 
system) (9, 13, 14). The transition from Bvg+ phase to Bvg– phase is termed phenotypic 
modulation. 
Although the BvgAS phosphorelay and transcriptional control of the BvgAS regulon are 
well characterized, the natural signals that impact BvgS activity and the mechanism by which 
these signals are perceived and integrated by this system are unknown. Of BvgS’s three putative 
sensory perception domains, the periplasmic VFTs have been studied most. Structure-function 
analyses support a model in which VFT2 (the domain closest to the membrane) is in a closed 
conformation in the absence of modulating signals, and that this conformation renders BvgS 
active (15, 16). Hence the ‘default’ state for BvgS is one in which it is an active kinase. Binding 
of NA to VFT2 alters its conformation and this change is apparently transduced across the 
membrane, which is proposed to cause reversal of the phosphorelay, resulting in the 
dephosphorylation of BvgA and a shift to the Bvg– phase (17). 
The role of the PAS domain in regulating BvgS activity is less understood. PAS domains 
are abundant in prokaryotic signal transduction proteins and have a conserved structure, which 
includes a core binding pocket composed of a central, five-stranded antiparallel beta sheet and 
flanking alpha helices (18). Despite their conserved structure, PAS domains can perceive a 
multitude of stimuli, either by directly binding a signal molecule or by sensing with the 
assistance of a co-factor, in addition to promoting protein-protein interactions that mediate signal 
transduction (19–22). The PAS domain of BvgS contains two perception motifs that are critical 
for PAS domain function in other regulatory proteins; a quinone binding motif [aliphatic-(X)3-H-
(X)2,3-(L/T/S)] and a highly conserved cysteine residue (C607) (23, 24). In vitro studies with the 
cytoplasmic portion of BvgS from B. pertussis showed that kinase activity was decreased in the 
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presence of an oxidized ubiquinone analog and that the histidine in the quinone binding motif 
(H643) contributed to this effect (23). Jacob-Dubuisson and colleagues hypothesized that H643 
may be involved in binding heme, but were unable to detect heme, or other cofactors, bound to 
the BvgS PAS domain (25). Their characterization of an H643A mutant of B. pertussis showed 
no defect in activation of the ptx promoter under aerobic conditions, but, instead, a defect in 
responding to NA and MgSO4. This group also investigated the importance of the conserved 
cysteine (C607) and found that a C607A mutant was similarly defective only in its ability to 
modulate in response to NA (25). Approximately one-third of BvgS homologs contain coiled-
coil domains instead of PAS domains. Jacob-Dubuisson and colleagues showed that a B. 
pertussis mutant in which the BvgS PAS domain was replaced with the coiled-coil domain from 
the BvgS homolog of Enterobacter cloacae was similar to wild-type bacteria in its ability to 
activate ptx expression and to respond to NA (26). Taking these and other observations together, 
this group concluded that the role of the BvgS PAS domain is primarily to transduce signals from 
the VFTs to the kinase domain and that it may not function as a sensory perception domain to 
sense signals on its own.  
Our laboratory has focused primarily on studying B. bronchiseptica because its broad 
host range allows us to study the role of Bordetella virulence factors and their regulation using 
natural host animal models (27, 28). We were motivated to investigate the role of the BvgS PAS 
domain during respiratory infection by our recent observation that maintenance of BvgS kinase 
activity in the lower respiratory tract (LRT) requires another TCS called PlrSR (29). PlrSR is a 
member of the NtrYX family of TCS, members of which are involved in sensing and responding 
to changes in redox status and anaerobiosis (30, 31). We hypothesized that, in the LRT, PlrSR 
controls expression of genes that contribute to electron transport-coupled oxidative 
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phosphorylation and that deletion of plrS results in an altered redox state at the cytoplasmic 
membrane that is sensed by BvgS, perhaps via the PAS domain, resulting in its inactivation (i.e., 
converting it from a kinase to a phosphatase). In this study, we constructed B. bronchiseptica 
mutants with amino acid substitutions in the BvgS PAS domain and characterized them in vitro 
and in vivo to test this hypothesis. 
Results 
Mutants used in this study  
To investigate the role of the BvgS PAS domain during infection, and to facilitate 
comparison of our results with those obtained with B. pertussis, we constructed mutant 
derivatives of B. bronchiseptica strain RB50 containing the same mutations as those that were 
present in the B. pertussis BPSM strains studied by Jacob-Dubuisson and colleagues (25, 26). 
Specifically, we constructed strains producing BvgS proteins in which H643 or C607 were 
replaced by alanine, and a strain in which the amino acids corresponding to the PAS domain 
were replaced with the analogous 47 amino acid (aa) region from the BvgS homolog of 
Enterobacter cloacae (Fig. 3.1B and 3.1C). We also constructed a strain in which BvgS C607 
was replaced with the isosteric aa serine. As controls, we included the Bvg+ and Bvg– phase-
locked strains RB53 (aka BvgSc) and RB54 (aka ∆bvgS), respectively.  
Contribution of the PAS domain in regulating BvgS activity in vitro 
To assess BvgS activity and sensitivity to modulating chemicals in our PAS domain 
mutants, we used two different gfp reporters; one containing the fhaB promoter (PfhaB), which 
contains high-affinity BvgA~P binding sites and therefore requires only very low levels of 
BvgA~P for activation, and one containing the B. pertussis ptxA promoter (PptxA), which contains 
low-affinity BvgA~P binding sites and requires high levels of BvgA~P for activation (9, 13, 32, 
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33). The lower-affinity BvgA~P binding sites allow the PptxA-gfp fusion to discern a broader 
range of BvgA~P levels (and hence BvgS kinase activities) than the PfhaB-gfp fusion. As 
expected, both promoters were activated in wild-type bacteria (WT), but not in the ∆bvgS 
mutant, when grown in SS broth at 37°C (Bvg+ phase conditions).  PfhaB-gfp expression was 
similar in the strain containing the bvgS-C3 mutation (BvgSc) to that in WT, while PptxA-gfp 
expression was much higher in BvgSc than in WT (Fig. 3.2A and 3.2B), suggesting that BvgS 
kinase activity (either autokinase activity or a subsequent step in the transfer of the phosphoryl 
group to the Hpt and ultimately to BvgA) is greater in BvgSc than in WT when grown in SS at 
37°C. When the bacteria were grown in medium containing 4 mM NA or 50 mM MgSO4 (Bvg
– 
phase conditions), PfhaB-gfp and PptxA-gfp expression was very low in the wild-type and ∆bvgS 
strains and remained high in BvgSc, demonstrating the requirement of BvgS for activation of 
these promoters and the insensitivity of BvgS to NA and MgSO4 in BvgS
C (Fig. 3.2A and 3.2B). 
The “PASless” mutant (BvgSEc, the strain in which the BvgS PAS domain was replaced 
with the analogous sequence from the BvgS homolog in E. cloacae) activated PfhaB-gfp and PptxA-
gfp to a greater level than WT when grown under Bvg+ phase conditions (Fig. 3.2A and 3.2B), 
suggesting that the PASless BvgS, like BvgSC, is a more active kinase than wild-type BvgS. 
Expression of PfhaB-gfp and PptxA-gfp was significantly decreased when BvgSEc was cultured in 
the presence of NA or MgSO4 compared to growth in the absence of these chemical modulators, 
demonstrating the ability of the PASless BvgS to sense and respond to these signals (Fig. 3.2A 
and 3.2B). However, expression of PfhaB-gfp and, for NA, PptxA-gfp, in BvgEc did not decrease to 
the same low-to-undetectable levels in response to modulators as in WT (Fig. 3.2A and 3.2B). 
One explanation for these results is that the PASless BvgS is somewhat less sensitive than wild-
type BvgS to MgSO4 and NA. However, as the PASless BvgS appears to be a more active 
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kinase, it is possible that it responded similarly to wild-type BvgS, but its decreased activity was 
still sufficient to activate these promoters to some extent, especially PfhaB, which requires only 
very low amounts of BvgA~P for activation. Regardless of the underlying mechanism, these data 
indicate that the PASless BvgS protein is capable of sensing and responding to MgSO4 and NA.   
The H643A strain activated PfhaB and PptxA similarly to BvgS
C and BvgSEc when cultured 
in SS medium at 37C, indicating that the H643A substitution does not disrupt BvgS’s ability to 
function as a kinase, and apparently makes it a more active kinase, in vitro (Fig. 3.2A and 3.2B). 
When grown in medium containing NA or MgSO4, PfhaB-gfp and PptxA-gfp expression was 
significantly reduced in the H643A mutant compared to growth in the absence of NA and 
MgSO4, indicating that BvgS containing the H643A substitution is capable of sensing and 
responding to these chemicals. As with the PASless BvgS, BvgS containing the H643A 
substitution may be somewhat less sensitive to MgSO4 and NA, or may not fully inactivate in 
response to 4 mM NA or 50 mM MgSO4 because of its apparent increased kinase activity.  
Substitution of C607 with alanine or serine affected BvgS activity differently, despite 
both substitutions ablating the reactivity of the cysteine. The C607A mutation resulted in 
increased PfhaB-gfp and PptxA-gfp expression (suggesting increased BvgS kinase activity) under 
Bvg+ phase conditions (Fig. 3.2A and 3.2B), while the C607S substitution resulted in decreased 
PptxA-gfp expression (suggesting decreased kinase activity or a defect in subsequent steps in the 
phosphorelay) under Bvg+ phase conditions. Both strains responded to MgSO4 and NA similarly 
to wild-type bacteria (Fig. 3.2A and 3.2B).  
In all of the BvgS PAS domain mutants, BvgS remained responsive to MgSO4 and NA, 
indicating that the PAS domain is not absolutely required for sensing these chemicals. However, 
the apparent level of BvgS activity and its sensitivity to MgSO4 and NA differed among strains, 
 
60 
suggesting that the PAS domain of BvgS does play a role in transducing signals sensed by the 
VFTs to the cytoplasmic HK, REC and HPT domains, which is consistent with previous reports 
(25). 
Characterization of pGFLIP-PflaA and pBam reporters in BvgS PAS domain mutants in 
vitro 
To investigate the role of the PAS domain in vivo, we sought to measure bacterial burden 
and BvgS activity in the respiratory tract. To measure BvgS activity in vivo, we used two 
reporters that we have used previously (29, 34, 35). pGFLIP-PflaA is a recombinase-based 
reporter that indicates whether the bacteria have expressed the flaA gene, and hence the Bvg– 
phase, at any time during the course of the experiment. Expression of flaA results in a conversion 
of the bacteria from GFP+ and Kmr to GFP– and Kms (34). By contrast, the pBam reporter 
provides an indication of whether the bacteria are in the Bvg– phase at the time of plating on BG-
blood agar. Upon integration into the chromosome at the bvgAS locus, the pBam plasmid causes 
decreased transcription of bvgAS via the low-level, constitutively active P2 promoter. When 
wild-type B. bronchiseptica RB50 containing pBam is grown under Bvg– phase conditions, 
transcription from P2 is reduced such that a small proportion of the bacteria (~5%) in the 
population lack sufficient BvgAS for positive autoregulation of bvgAS (via the P1 promoter). As 
a consequence, ~5% of the bacteria are unable to efficiently transition to the Bvg+ phase when 
transferred to Bvg+ phase growth conditions and form larger, flatter, less hemolytic colonies 
termed LCPs (for large colony phenotype) (35). Although this reporter vastly underestimates the 
number of bacteria that are in the Bvg– phase at the time of sampling, it has proven useful in 
discerning differences in BvgAS activity during growth in vitro and in the lower respiratory tract 
(LRT) (29, 35). 
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We first characterized the use of pGFLIP-PflaA and pBam in our PAS domain mutants in 
vitro. When grown overnight in SS broth at 37°C (Bvg+ phase conditions), all strains maintained 
GFP fluorescence and formed few (<1%) LCPs, indicating the bacteria did not modulate under 
these conditions (Fig. 3.3A-D). Consistent with our previous results (29), when grown with 
either 4 mM NA or 50 mM MgSO4 (Bvg
– phase conditions), nearly 100% of WT bacteria lost 
GFP fluorescence and ~2-10% formed LCPs, indicating that nearly 100% of the bacteria had 
modulated to the Bvg– phase in response to these chemicals and were in the Bvg– phase at the 
time of plating (Fig. 3.3A-D). For the BvgSEc, C607A, and C607S strains, a majority of bacteria 
recovered after growth with NA and MgSO4 had also lost GFP fluorescence, indicating that they 
had modulated to the Bvg– phase like WT. By contrast, very few GFP– colonies were recovered 
for the H643A mutant, demonstrating the inability of this strain to modulate to the Bvg– phase 
sufficiently to result in activation of PflaA in response to NA and MgSO4. Taken with the PfhaB-gfp 
and PptxA-gfp fusion data, these results indicate that although BvgS with the H643A substitution 
is able to sense NA and MgSO4, it does not dephosphorylate BvgA~P as completely as wild-type 
BvgS such that PflaA is expressed, that is, it appears to modulate only partially. 
In addition to indicating whether the bacteria are phenotypically Bvg– phase at the time of 
plating, the pBam reporter provides an indication of how quickly BvgS transitions from an 
inactive to active state, because LCPs are formed by delayed or defective positive autoregulation 
of the bvgAS promoter (which requires BvgA~P to bind to, and activate transcription from, the 
high-affinity binding sites upstream of P1) (35). The proportion of LCPs for the BvgSEc and 
H643A mutants after growth in NA were lower than for WT, consistent with BvgS in these 
strains having increased kinase activity (and hence increased positive autoregulation) compared 
to wild-type BvgS, as suggested by the PptxA-gfp data (Fig. 3.2B). By contrast, the C607S mutant 
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formed dramatically more LCPs than WT bacteria after growth in NA, consistent with this BvgS 
protein having decreased kinase activity compared to wild-type BvgS, which is also consistent 
with the PptxA-gfp data. Altogether, these results indicate that the pGFLIP-PflaA and pBam 
reporters should be reliable indicators of BvgS activity in our PAS domain mutants in vivo. 
The PAS domain is not required for BvgS kinase activity in the LRT in PlrSWT bacteria 
One hypothesis for how PlrSR influences BvgS activity when the bacteria are in the LRT 
is that the BvgS PAS domain senses an activating signal that requires PlrSR and is needed for 
maintenance of BvgS kinase activity (Fig. 3.S1A). This signal would be absent in a ∆plrS mutant 
leading to BvgS inactivation (Fig. 3.S1B). We predicted that if this scenario were true, the 
PASless BvgS in BvgSEc would be unable to sense the PlrSR-dependent activating signal and 
hence BvgS would fail to function as a kinase in bacteria with wild-type PlrSR (as well as in 
∆plrS bacteria). To test this hypothesis, we inoculated mice intranasally with WT and BvgSEc 
containing pGFLIP-PflaA and pBam and determined the number of colony forming units (cfu), 
GFP fluorescence, and LCP formation of bacteria recovered from the nasal cavity (NC) and right 
lung lobes at 0, 1, and 3 days post-inoculation. The BvgSEc mutant colonized the NC and lungs 
similar to WT and showed no evidence of modulation (no conversion to GFP– and few, if any, 
LCPs) (Fig. 3.4A-C), indicating that PASless BvgS had maintained kinase activity throughout 
the infection. Therefore, either our initial hypothesis is wrong or the PASless BvgS protein no 
longer requires a PlrSR-dependent activating signal to initiate kinase activity in the LRT.  
The C607S substitution hinders BvgS kinase activity and bacterial colonization in the lower 
respiratory tract (LRT) of mice  
We also inoculated mice intranasally with WT, H643A, C607A, and C607S containing 
pGFLIP-PflaA and pBam to determine if the conserved histidine or cysteine residues in the PAS 
domain contribute to maintenance of BvgS kinase activity in vivo. While the H643A and C607A 
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mutants colonized the NC and lungs similar to WT and showed no evidence of modulation (no 
conversion to GFP– and few, if any, LCPs) (Fig. 3.4A-C), the C607S mutant was defective for 
colonization in the lungs and a small proportion of the C607S bacteria recovered from the NC 
and lungs had modulated, as indicated by the loss of GFP and development of LCPs (Fig. 3.4B 
and 3.4C). These data are consistent with the in vitro data suggesting that the H643A and C607A 
mutants have increased BvgS kinase activity while the C607S mutant has decreased BvgS kinase 
activity when grown under Bvg+ phase conditions. If these proteins function in vivo as they do in 
vitro, our data suggest that decreased BvgS kinase activity, but not increased BvgS kinase 
activity, is detrimental to the ability of the bacteria to colonize the LRT, which is consistent with 
previous studies that demonstrate the necessity of the Bvg+ phase for mammalian respiratory 
tract infection (4, 36).  
A role for the BvgS PAS domain is revealed in the absence of PlrS in the LRT 
A second hypothesis for how PlrSR influences BvgS activity when the bacteria are in the 
LRT is that PlrSR prevents the generation of a signal that would inhibit BvgS kinase activity 
(Fig. 3.S1C). In a ∆plrS mutant, this inactivating signal would accumulate, resulting in loss of 
BvgS kinase activity (Fig. 3.S1D). If true, and if that signal is sensed by the BvgS PAS domain, 
then PASless BvgS, and potentially some of the PAS domain point mutants, would be insensitive 
to the inactivating signal and remain active in a ∆plrS mutant. To test this hypothesis, we deleted 
plrS in the BvgS PAS domain mutants and used the pGFLIP-PflaA and pBam reporters to evaluate 
BvgS activity in these strains in vivo. Similar to and as previously shown for the ∆plrS mutant 
(29), all strains containing the PAS domain mutations in addition to the ∆plrS mutation were 
severely defective for survival in the LRT, but colonized the NC similarly to WT (Fig. 3.5A). 
(To unclutter Fig. 3.5, asterisks denoting statistical significance are shown only for comparisons 
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between the double mutants and the parental ∆plrS mutant.) Similar to the parental ∆plrS strain, 
the C607A ∆plrS and C607S ∆plrS double mutants showed evidence of modulation in the LRT, 
with a large percentage of GFP– bacteria recovered from the lungs at days 1 and 3 post-
inoculation (Fig. 3.5B). A small proportion of bacteria of these same strains also modulated in 
the NC. These data suggest that C607 is not involved in the modulation of BvgS that occurs in 
the LRT in the absence of PlrS. Interestingly, despite the large number of GFP– cfu recovered for 
the C607A ∆plrS mutant, very few LCPs were generated (Fig. 3.5C), suggesting that, in this 
strain, BvgS functions more efficiently as a kinase than wild-type BvgS once modulatory 
pressure is removed, consistent with the in vitro data.  
For the BvgSEc ∆plrS and H643A ∆plrS mutants, and in contrast to the ∆plrS mutant, few 
GFP– colonies and LCPs were recovered from the LRT (Fig. 3.5B and 3.5C), indicating that 
BvgS remained active in these strains, supporting the hypothesis that the PAS domain senses a 
negative signal that accumulates in the absence of PlrS in the LRT. In vitro, both of these mutant 
BvgS proteins were able to sense MgSO4 and NA, however, only the BvgSEc mutant was capable 
of modulating to the Bvg– phase sufficiently to activate PflaA in response to both chemicals. The 
fact that the BvgSEc ∆plrS mutant did not activate PflaA in vivo indicates that the modulating 
signal sensed by BvgS in the ∆plrS mutant background in the LRT is different, or is sensed 
differently, than NA or MgSO4 in vitro. These results suggest that the PAS domain, rather than 
the VFTs, is responsible for sensing the modulating signal that occurs in the LRT in the absence 
of PlrS. These results are the first, of which we are aware, to implicate the PAS domain of BvgS 
as an independent perception domain capable of influencing the activity of BvgS and support the 
hypothesis that the BvgS PAS domain may sense an inactivating signal that is regulated by 




The fact that BvgS contains three putative signal perception domains and therefore has 
the potential to integrate multiple distinct environmental signals has been known for 20 years 
(21, 37, 38). To date, however, roles only for the VFT domains have been identified (15–17). 
Studies investigating the purpose of the PAS domain have suggested a role only in transducing 
signals sensed by the VFTs to the cytoplasmic signaling domains (25, 26). Our data support this 
role for the PAS domain. However, our data collected from experiments investigating BvgS 
signaling during mammalian respiratory tract colonization indicate that the PAS domain can also 
function as a signal perception domain that is capable of influencing BvgS activity independently 
from the VFTs.  
Our results cannot definitively distinguish whether the PAS domain senses an activating 
signal that is dependent on PlrSR (Fig. 3.S1A) or senses an inhibitory signal that is produced in 
the absence of PlrSR (Fig. 3.S1C). Regardless, our data support an important role for the PAS 
domain in sensing a signal(s) independent of the VFT domains. Our in vitro transcriptional 
analyses showed that both wild-type BvgS and PASless BvgS can sense NA and MgSO4, 
presumably via the VFT domains, and in response they modulate the bacteria to the Bvg– phase. 
In vivo, wild-type BvgS was also sensitive to a PlrS-dependent signal in the LRT (the ∆plrS 
strain modulated to the Bvg– phase in the LRT), however, PASless BvgS was insensitive to this 
signal, indicating that this in vivo signal 1) is sensed differently than NA or MgSO4 (i.e., likely 
not via the VFTs) and 2) specifically requires the PAS domain for perception.  
Similar to the PASless BvgS protein, BvgS with the H643A substitution was also 
insensitive to the PlrS-dependent signal in vivo; the H643A strain did not activate the PflaA 
promoter in the absence of PlrS in the LRT. Although this BvgS protein was capable of sensing 
NA and MgSO4 in vitro, it did not modulate sufficiently to de-repress PflaA under these in vitro 
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conditions, and therefore, we cannot rule out that this strain did not modulate to some degree in 
vivo while in the LRT.  
PlrSR is a member of the NtrYX family of TCS (39). Although some NtrYX family 
members are involved in nitrogen homeostasis, others, such as those in Brucella abortus and 
Neisseria gonorrhoeae, control genes involved in bacterial respiration (such as those encoding 
high affinity cytochrome oxidases) in response to low oxygen (30, 40). We hypothesize that 
PlrSR may similarly control the expression of genes that contribute to electron transport-coupled 
oxidative phosphorylation. Absence of appropriate cytochrome oxidases when the bacteria are in 
the LRT would likely alter the redox status of the electron transport chain components, such as 
ubiquinone, and would also likely prevent bacterial growth. Bock and Gross showed that BvgS 
kinase activity is inhibited by oxidized ubiquinone in vitro and that the H643 residue, which 
resides within a putative quinone binding motif in the BvgS PAS domain, contributes to BvgS’s 
sensitivity to this redox-active molecule (23). We are currently investigating whether PlrSR 
controls the expression of the multiple operons encoding high and low affinity cytochrome 
oxidases and, if so, their role in controlling BvgS activity in the LRT.  
Our data suggest that the conserved cysteine residue (C607) does not contribute to the 
sensing capacity of BvgS (i.e., the ability to modulate) either in vitro or in vivo. However, this 
residue is important for maintaining BvgS kinase activity. In vitro, the C607A substitution 
resulted in increased PfhaB and PptxA transcription, while the C607S substitution resulted in 
decreased PptxA transcription. In vivo, the C607S mutant modulated (sufficiently to activate PflaA) 
to a greater extent than wild-type bacteria in both the nasal cavity and lungs, which is also 
consistent with this substitution reducing the kinase activity of BvgS, although it is also possible 
that the C607S substitution affected protein stability. (Decreased protein stability is unlikely to 
 
67 
explain altered activity for the other BvgS mutants as they each had increased kinase activity.) 
Although more experiments will be required to determine the contribution of C607, one 
possibility is that C607 forms a disulfide bond between BvgS monomers in the kinase active 
conformation and that this conformation is sterically altered (rendering BvgS inactive) when the 
disulfide bond is reduced, or when the cysteine is replaced by serine with its hydroxyl groups. 
Replacement of the cysteine with alanine may not disrupt the active conformation, and may even 
make it less susceptible to inadvertent disruption, hence the C607A mutant is a better kinase. The 
fact that the C607A (and C607S) mutants were capable of modulating, however, suggests that 
reduction of the disulfide bond that could occur between BvgS monomers is not necessary for 
sensing and responding to modulating signals, at least not those signals tested in our 
experiments. 
Overall, our results are generally consistent with those of Jacob-Dubuisson and 
colleagues who demonstrated a role for the BvgS PAS domain in regulating efficient BvgS 
signal transduction (25). These results are not surprising as BvgS from B. bronchiseptica and B. 
pertussis are functionally interchangeable and the PAS domain is highly conserved between 
species (only differing by 2 amino acid residues) (5, 41). We did, however, identify some 
nuanced differences in BvgS activity between B. bronchiseptica and B. pertussis. When 
assessing BvgS kinase activity, our results indicated that BvgS in B. bronchiseptica fails to fully 
activate when the bacteria are grown under laboratory conditions. We showed that replacement 
of some amino acids in the PAS domain enhanced BvgS kinase activity compared to WT, 
indicating that the PAS domain influences BvgS kinase activity in B. bronchiseptica. This 
enhancement of kinase activity was not observed in B. pertussis with similar substitutions (25, 
26), suggesting that BvgS may already be maximally active in vitro and/or the PAS domain does 
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not influence BvgS activation in B. pertussis. These data could explain why some strains of B. 
pertussis appear less sensitive to modulating signals in vitro (NA and MgSO4) compared to most 
B. bronchiseptica isolates (5). If BvgS from B. pertussis has higher kinase activity in vitro, it is 
likely that more modulatory signal would be required to inhibit BvgS kinase activity sufficiently 
to noticeably decrease vag expression. We also observed that modification of the BvgS PAS 
domain had different effects on BvgS’s responsiveness to NA and MgSO4 in each species. In B. 
bronchiseptica, BvgS with the H643A substitution remained responsive to NA and MgSO4, 
while, in B. pertussis, this substitution rendered BvgS insensitive to both chemicals (25). 
Similarly, the C607A substitution made BvgS from B. pertussis insensitive to modulation by 
NA, however, BvgS responsiveness was unchanged by this substitution in B. bronchiseptica 
(25). As the VFTs are implicated in sensing NA and MgSO4, the differences we observed are 
likely due to the significant variability of amino acid sequence encoding the BvgS VFT domains 
in B. bronchiseptica and B. pertussis (5, 41). While our data corroborate a role for the PAS 
domain in facilitating the transduction of signals though the BvgS protein, our results also 
highlight that it is important to consider how the VFT domains may influence the function of the 
PAS domain and how the synergy of all perception domains contribution to the ultimate output 
of BvgS activity.    
The VFT domains and the PAS domain serve as independent points of signal integration 
within BvgS. It is well known that the modulatory signals NA and MgSO4 require the VFT 
domains for perception in vitro and based on our working model, the PAS domain is perhaps 
sensitive to the redox state of ubiquinone. The natural signals sensed by BvgS, however, remain 
unknown. By having multiple separate signaling domains, BvgS has the potential to control 
bacterial gene expression appropriately in many environments. For example, in the mammalian 
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LRT BvgS kinase activity is essential for bacterial survival, therefore, it is likely that both the 
VFT domains and the PAS domain are in an ‘on’ or active conformation, thus permitting BvgS 
activity. In a ∆plrS mutant in the LRT, however, BvgS is inactive and the PAS domain is likely 
in an ‘Off’ or inactive conformation based on our results. This environment, although artificial, 
potentially mimics a naturally occurring environment in which the PAS domain can integrate a 
signal that overrides an activating input sensed by the VFT domains, indicating the possibility 
that the VFT domains and the PAS domain could obtain various combinations of conformations, 
rendering BvgS on or off depending on which domain’s influence dominates within the specific 
environment encountered by the bacteria. Interestingly, not all BvgS homologs have PAS 
domains, suggesting that bacteria with simplified BvgS proteins perhaps do not encounter such a 
diverse range of environments and, therefore, do not require BvgS to integrate multiple signals 
(26). The fact that a PAS domain in BvgS has been maintained in Bordetella is indicative of the 
critical role this domain plays in the regulation of this important TCS.  
Materials and Methods 
Bacterial strains, plasmids, and growth conditions 
All bacterial strains and plasmids used in this study are listed in Table 1. Escherichia coli 
strains were grown using Lysogeny broth (LB) or agar at 37C. B. bronchiseptica strains were 
grown on Bordet-Gengou (BG) agar supplemented with 7.5% defibrinated sheep blood or in 
Stainer-Scholte (SS) broth supplemented with SS supplement at 37°C (42). As needed, media 
was supplemented with ampicillin (Amp; 100 g/mL), streptomycin (Sm; 20 g/mL), 
gentamicin (Gm; 30 g/mL), kanamycin (Km; E.coli at 50 g/mL or B. bronchiseptica at 125 
g/mL), or diaminopimelic acid (DAP; 300 g/mL).   
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Construction of B. bronchiseptica BvgS PAS domain mutant strains  
DNA manipulation and cloning were performed according to standard methods (43). All 
restriction enzymes and DNA ligase were obtained from New England Bio Labs. High-fidelity 
PFU Ultra II DNA polymerase was used for the construction of all allelic exchange vectors used 
in this study. GoTaq DNA polymerase was used for screening purposes during plasmid and 
strain construction. All enzymes were used according to the manufacturer’s instructions. The 
primers used in this study are listed in Table 2. All primers were synthesized by Eton 
Biosciences and purified using a standard desalting method.   
To create the BvgSEc mutation, primers MAB85-MAB90 were used to generate an 
approximately 1.2 kb DNA fragment, which contained a 141 bp sequence encoding an α-helical 
linker from the BvgS homolog in Enterobacter cloacae (GI: 915610361), flanked by 
homologous sequences (500 bp each) corresponding to the regions 5’ and 3’ to the PAS domain 
of the B.bronchiseptica bvgS gene. Individual point mutations in bvgS (H643A, C607A, and 
C607S) were generated by constructing allelic exchange plasmids containing an approximately 
1.0 kb DNA fragment of the bvgS sequence, centered on the PAS domain, with exact homology 
to bvgS except for the desired substitution and a unique restriction enzyme digestion site, used 
for screening. Primers used to generate the most 5’ and 3’ ends of the DNA fragments for each 
mutant were designed to include a BamHI restriction site at the 5’ end and a SacI restriction at 
the 3’ end, which were used to clone the DNA fragments into the allelic exchange plasmid 
pEG7S (7). Standard methods were then used to deliver this plasmid to RB50 and ∆plrS strains 
by conjugation using RHO3 cells. Double homologous recombination events that introduced the 
desired mutation into the chromosome were selected for using 15% sucrose (w/v) and screened 
for by restoration of BvgS activity indicated by the presence of hemolysis on BG-blood agar or 
through restriction digestion using the unique restriction enzyme site introduced for point 
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mutants. Sanger sequencing was used to verify each mutation in bvgS. The pGFLIP-PflaA and 
pBam reporters were introduced into each mutant strain, using tri-parental mating with 
conjugative RHO3 or by homologous recombination, respectively. Introduction of each reporter 
on to the chromosome was verified using PCR.  
Construction of PptxA-gfp and PfhaB-gfp transcriptional reporters 
To construct a GFP transcriptional reporter for PptxA, the ptxA promoter (position -5 to -
220 upstream of ptxA coding sequence) was amplified by PCR from B. pertussis Tohama I. To 
construct a GFP transcriptional reporter for PfhaB, the fhaB promoter (position -5 to -254 
upstream of fhaB coding sequence) was amplified by PCR from B. bronchiseptica RB50. PCR 
products were then digested and cloned into the pUCgfpMAB plasmid using EcoRI and HindIII 
restriction sites. The resulting plasmids were subsequently sequenced to verify that each 
promoter was correctly fused 5’ to the S12 RBS and gfp. Each reporter plasmid was then 
introduced into WT, BvgSC, ∆bvgS, BvgSEc, H643A, C607A, and C607S strains using tri-
parental mating with conjugative RHO3. A strain of RB50 was also engineered to contain the 
pUCgfpMAB plasmid without a promoter driving gfp expression as a control 
(RB50::pUCgfpMAB-EV). Reporter delivery to the Tn7 site was confirmed by PCR in each 
strain. 
Transcription of PptxA-gfp and PfhaB-gfp reporters in vitro 
To analyze expression of the PptxA-gfp and PfhaB-gfp transcriptional reporters under Bvg
+ 
phase conditions, strains were grown on BG-blood agar supplemented with kanamycin at 37 °C 
until colonies formed. Approximately 3-4 colonies were used to inoculate liquid SS media 
containing streptomycin and kanamycin, with or without 4 mM nicotinic acid (NA) or 50 mM 
MgSO4, depending on the experimental conditions tested. All cultures were incubated overnight 
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for ~18 h at 37 °C on a roller. Each overnight culture was then sub-cultured to an OD of 0.3 per 
mL into fresh liquid SS media containing streptomycin and kanamycin, with or without 4 mM 
nicotinic acid (NA) or 50 mM MgSO4, depending on the experimental conditions tested. 
Subcultures were incubated for ~4 h at 37°C while rotating. Subsequently, 100 L of each 
culture were transferred to a well of a 96-well, flat bottom, polystyrene plate, and the OD600 and 
RFU at excitation A485 and emission A535 (to detect GFP) were measured on a Perkin-Elmer 
Victor3 1420 Multi-label plate reader. Total GFP expression was normalized by initial 
subtraction of background fluorescence, as determined from the RB50::pUCgfpMAB-EV strain, 
and normalization to the OD600 for each sample. Cultures were prepared and tested in duplicate 
and three experimental replicates were completed. Normalized GFP/OD600 values were 
averaged across all replicates. 
Characterization of pGFLIP-PflaA and pBam reporters in vitro  
Strains containing pGFLIP-PflaA and pBam reporters were grown overnight in SS medium 
with streptomycin and gentamycin, with and without 50 mM MgSO4 or 4 mM nicotinic acid. 
After incubation at 37 °C for 24 h on a rotating incubator, an aliquot of cells from each 
experimental condition was diluted to a concentration of 3 x 103 cells/mL with 1X PBS and 
plated on BG-blood agar in duplicate. Plates were incubated for 72 h at 37 °C. White light and 
GFP fluorescence images of each plate were captured using a G:Box Imaging System (Syngene). 
Total cfu, GFP positive colonies, and LCP colonies were enumerated using the colony analysis 
protocol of the GeneTools Software package (Syngene). The total number of GFP negative 
colonies was calculated by subtracting the number of GFP positive colonies from the total 
number of colonies isolated. The percent GFP negative colonies and percent LCP colonies were 
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calculated based on the total number of colonies isolated. Each in vitro experimental condition 
was tested twice. 
Evaluation of B. bronchiseptica modulation in vivo 
Bacteria were cultured overnight at 37 °C in SS media with streptomycin, kanamycin, 
and gentamicin to maintain bacteria in the Bvg+ phase (42). Six-week-old female BALB/c mice 
from Jackson Laboratories were inoculated intranasally with 7.5 × 104 cfu of B. bronchiseptica 
strains (containing the pGFLIP-PflaA and pBam reporters) in 50 μL of 1 X DPBS. At each time 
point reported, right lung lobes and nasal cavity tissue were harvested and homogenized in 1 X 
DPBS using a mini-beadbeater. Dilutions of the tissue homogenates were then plated on BG-
blood agar and grown at 37C for 72 h. White light (to enumerate total cfu and LCPs) and blue 
light (to enumerate GFP+ colonies) images of each plate were captured using a G:Box Imaging 
System (Syngene). Total cfu, GFP positive colonies, and LCP colonies were enumerated using 
the colony analysis protocol of the GeneTools Software package (Syngene). The total number of 
GFP negative colonies was calculated by subtracting the number of GFP positive colonies from 
the total number of colonies isolated. The percent GFP negative colonies and percent LCP 
colonies were calculated by determining the ratio of GFP negative colonies or LCP colonies to 
the total number of colonies isolated. 
Ethics statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health (44). All animals 
were properly anesthetized for inoculations, monitored regularly, and euthanized when 
moribund. Efforts were made to minimize suffering. Our protocol was approved by the 
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University of North Carolina Institutional Animal Care and Use Committee (Protocol ID: 16-
246).  
Statistical analysis 
Statistical analysis was performed using Prism 8.0.1 software from GraphPad Software. 
Statistical significance of all experimental data was determined using Mann-Whitney analysis. A 
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Figure 3.1. The sensor kinase, BvgS, has a unique PAS domain, which may play a role in 
signal perception. (A) Schematic of the two-component phosphor-relay system BvgAS. BvgS is 
an unorthodox His-Asp-His sensor kinase, comprised of tandem, periplasmic, venus fly-trap 
(VFT) domains followed by a transmembrane (TM) domain, a cytoplasmic Per/Arnt/Sim (PAS) 
domain, a histidine kinase (HK) domain, a receiver (REC) domain, and a histidine 
phosphotransfer (Hpt) domain. BvgA is a classical DNA-binding response regulator, comprised 
of a receiver (REC) domain and a helix-turn-helix (HTH) DNA-binding domain. When active, 
BvgS autophosphorylates and the phosphoryl group is transferred to the REC and Hpt domains 
and then to BvgA. The phosphorylated form of BvgA (BvgA~P) can bind DNA and activate or 
repress gene expression. Although it has not been formally demonstrated, under inactivating 
conditions it is likely that the phosphorelay is reversed and the phosphoryl group is transferred 
from BvgA to the Hpt and REC of BvgS. (B) Amino acid sequence of the BvgS PAS domain 
(highlighted in yellow) and flanking domains (TM domain highlighted in grey and the HK 
domain highlighted in green). Red arrows highlight the highly conserved cysteine (C607) and 
histidine (His643) residues of the BvgS PAS domain that were targeted for mutagenesis. Grey 
numbers correspond to amino acid position in BvgS. (C) Schematic of the amino acid sequence 
of the alpha-helical linker (underlined in red) that was used to replace the BvgS PAS domain in 
the strain BvgSEc. The amino acid sequence of the N-terminal TM domain is highlighted in grey 
and the C-terminal HK domain is highlighted in green. Grey number corresponds to amino acid 





Figure 3.2. In B. bronchiseptica, the PAS domain influences BvgS kinase activity and 
sensitivity to chemical modulation in vitro. Transcriptional analysis of PptxA and PfhaB activity in 
wild-type (WT), BvgSC, ∆bvgS, BvgSEc, H643A, C607A, and C607S strains of B. bronchiseptica 
using the gfp based reporters. All strains were cultured in Stainer Scholte (SS) broth (Bvg+ 
growth conditions, black bars), in SS with 4mM nicotinic acid (Bvg– growth conditions, blue 
bars), or in SS with 50mM MgSO4 (Bvg
– growth conditions, orange bars) at 37 °C with 
agitation. (A) Activity of the high-affinity BvgA~P PfhaB promoter was determined using the 
PfhaB-gfp reporter and (B) activity of the low-affinity BvgA~P PptxA promoter was determined 
using the PptxA-gfp reporter. Colored bars represent the mean normalized GFP fluorescence per 
cell (GFP/OD600) calculated from triplicate experiments. Error bars represent the standard 
deviation of normalized GFP/OD600 for each data set. Statistical significance (Mann-Whitney, P 
< 0.05) of values for each strain compared to WT under Bvg+ phase growth conditions (SS 
Broth) is indicated by a single * and statistically significance comparisons of values for a single 
strain cultured in each growth condition (SS Broth vs NA or SS Broth vs MgSO4) is indicated by 






Figure 3.3. The PAS domain is important for BvgS inactivation in response to known 
modulatory chemicals in vitro. In vitro analysis of wild-type (WT), BvgSEc, H643A, C607A, 
and C607S modulation in response to the chemical signals nicotinic acid (NA) and magnesium 
sulfate (MgSO4). All strains contain the plasmid reporters pGFLIP-PflaA and pBam.  Strains were 
cultured under Bvg+ (SS broth) and under two different Bvg– phase growth conditions (SS broth 
with 4 mM NA or 50 mM MgSO4) at 37 °C for ∼18 h with agitation and subsequently plated on 
BG-blood solid agar to enumerate the percentage of GFP− colonies (A and C) and LCPs (B and 
D). NA was used as the modulatory stimulus in (A) and (B). MgSO4 was used as the modulatory 
stimulus in (C) and (D). GFP negativity indicates bacterial modulation and loss of BvgS kinase 
activity. LCPs indicate bacteria present in the Bvg– phase when plated. Mann-Whitney analysis 
was used to compare % GFP negative values and % LCP values for all mutant strains compared 







Figure 3.4. A conserved cysteine residue in the PAS domain is important for maintaining 
BvgS kinase activity during respiratory tract colonization of mice. (A) Colonization of the 
nasal cavity (top) and right lung (bottom) tissue in female BALB/cJ mice by wild type (WT; 
black circles), BvgSEc (blue squares), H643A (green hexagons), C607A (yellow diamonds), and 
C607S (purple triangles) strains on days 0, 1, and 3 post-inoculation. All strains contain the 
plasmid reporters, pGFLIP-PflaA and pBam. Mice were inoculated with 7.5 x10
4 cfu via the 
external nares. Each symbol represents a single animal, with the mean colonization depicted as 
short horizontal bars. (B) Percentage of GFP negative (% GFP–) bacteria recovered from the 
nasal cavity (top) and right lung (bottom). GFP negativity indicates bacterial modulation and loss 
of BvgS kinase activity. (C) Percentage of large colony phenotype (LCP) producing bacteria 
recovered from the nasal cavity (top) and right lung (bottom). LCPs indicate bacteria present in 






Figure 3.5. The PAS domain is required for BvgS modulation in response to PlrSR 
dysfunction during LRT colonization. (A) Colonization of the nasal cavity (top) and right lung 
(bottom) tissue in female BALB/cJ mice by wild type (WT; black circles), ∆plrS (red triangles), 
∆plrS-BvgSEc (blue squares), ∆plrS-H643A (green hexagons), ∆plrS-C607A (yellow diamonds), 
and ∆plrS-C607S (purple triangles) strains on days 0, 1, and 3 post-inoculation. All strains 
contain the plasmid reporters, pGFLIP-PflaA and pBam. Mice were inoculated with 7.5 x10
4 cfu 
via the external nares. Each symbol represents a single animal, with the mean colonization 
depicted as short horizontal bars. Homogenate from each organ was used to determine bacterial 
burden shown in graph A and in vivo bacterial modulation shown in graphs B and C. (B) 
Percentage of GFP negative (% GFP–) bacteria recovered from the nasal cavity (top) and right 
lung (bottom). GFP negativity indicates bacterial modulation and loss of BvgS kinase activity. 
(C) Percentage of large colony phenotype (LCP) producing bacteria recovered from the nasal 
cavity (top) and right lung (bottom). LCPs indicate bacteria present in the Bvg– phase when 
recovered. Mann-Whitney analysis was used to compare CFU, % GFP negative, and % LCP 
values for all BvgS PAS domain ∆plrS double mutants compared to the ∆plrS strain. Statistical 




Figure 3.S1. The PAS domain of BvgS may sense an activating or inactivating signal in the 
LRT. (A) Schematic depicting how the PAS domain may be required to sense a PlrS-dependent 
activating signal that is required to maintain BvgS kinase activity in the LRT. Genes encoding a 
protein(s) required for the generation of an activating signal are regulated by the PlrSR TCS. The 
BvgS PAS domain is required for sensing this activating this signal and BvgS can function as a 
kinase. (B) Without PlrS, generation of the activating signal does not occur and BvgS would be 
off. (C) Schematic depicting how the PAS domain may sense a signal that inactivates BvgS in 
the LRT. Normally, the activity of a protein(s) encoded by a gene(s) regulated by the PlrSR 
system would inhibit the generation of an inactivating signal. (D) However, without PlrS this 
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Table S1. Bacterial Strains and Plasmids Used in this Study 
Bacterial Strain or Plasmid Description Reference 
E.coli Strains   
DH5α Molecular cloning strain  GIBCO BRL 
RHO3 Conjugation strain; Kms Δasd ΔaphA, DAP auxotroph  (35) 
B. bronchiseptica Strains   
RB50 (WT) Wild-type B. bronchiseptica strain; Smr (4) 
BvgSC (RB53) RB50 containing the bvgS R570H point mutation; Smr (4) 
∆bvgS (RB54) RB50 containing an in-frame deletion of bvgS; Smr (4) 
∆plrS RB50 containing an in-frame deletion of plrS; Smr (39) 
BvgSEc 
RB50 containing bvgS with sequence encoding the PAS domain (bp 1690 to bp 2154) replaced with sequence 
encoding an α-helical linker from the BvgS homolog od Enterobacter cloacae; Smr 
This Study 
H643A RB50 containing the bvgS H643A point mutation; Smr This Study 
C607A RB50 containing the bvgS C607A point mutation; Smr This Study 
C607S RB50 containing the bvgS C607S point mutation; Smr This Study 
∆plrS – BvgSEc 
RB50 containing an in-frame deletion of plrS and bvgS with sequence encoding the PAS domain (bp 1690 to 
bp 2154) replaced with sequence encoding an α-helical linker from the BvgS homolog of Enterobacter 
cloacae; Smr 
This Study 
∆plrS – H643A RB50 containing the bvgS H643A point mutation and a deletion of plrS; Smr This Study 
∆plrS – C607A RB50 containing the bvgS C607A point mutation and a deletion of plrS; Smr This Study 
∆plrS – C607S RB50 containing the bvgS C607S point mutation and a deletion of plrS; Smr This Study 
Plasmids   
pEG7S 
Suicide plasmid conferring sucrose sensitivity when integrated into the B. bronchiseptica chromosome, used 
for allelic exchange mutagenesis; Gmr 
(4) 
pUCgfpMAB attTn7 site-specific integration vector containing gfp; Kmr This Study 
pTNS3 attTn7 transposase expression vector containing tnsABCD; Ampr (34) 
pGFLIP-PflaA  pGFLIP with flp recombinase driven by the RB50 flaA promoter; Ampr, Kmr  (34) 
pBam 
Plasmid that integrates into the Bordetella chromosome 5’ to the bvgAS locus and allows for generation of 
LCPs; Ampr, Gmr 
(35) 
pPAS-R4 
Plasmid containing the 141 bp, a-helical linker sequence from the BvgS homolog of Enterobacter cloacae, 
which was used to replace the sequence encoding the PAS domain in RB50 bvgS; Ampr 
(26) 
PptxA-gfp pUCgfpMAB with gfp driven by the B.pertussis Tohama I ptxA promoter; Kmr This Study 
PfhaB-gfp pUCgfpMAB with gfp driven by the RB50 fhaB promoter; Kmr This Study 
pEG7S-BvgSEc 
pEG7S plasmid containing a ~1.2 kb DNA fragment with a 141 bp sequence that encodes an α-helical linker 
sequence from the BvgS homolog in Enterobacter cloacae situated between 5’ and 3’ homologous sequences 
(500 bp each) that flank the PAS domain in RB50 bvgS 
This Study 
pEG7S-BvgS H643A 
pEG7S plasmid containing a ~1 kb DNA fragment encoding the H643A mutation and a silent BseRI mutation 
located 2 codons downstream of the H643 codon in bvgS 
This Study 
pEG7S-BvgS C607A 
pEG7S plasmid containing a ~1 kb DNA fragment encoding the C607A mutation and a silent AflII mutation 
located 4 bp downstream of the C607 codon in bvgS 
This Study 
pEG7S-BvgS C607S 
pEG7S plasmid containing a ~1 kb DNA fragment encoding the C607S mutation and a silent AflII mutation 
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MAB13 Used in construction of pEG7S-BvgS H643A GCATGAGCTCAACCGCTACTTCGCC Forward 
MAB14 Used in construction of pEG7S-BvgS H643A GTGAGGAGGAACTCGGCCATCTCGCGAGCCA Reverse 
MAB15 Used in construction of pEG7S-BvgS H643A AGATGGCCGAGTTCCTCCTCACGCGCATGTC Forward 
MAB16 Used in construction of pEG7S-BvgS H643A ATGCGGATCCGAAGACGCGGATCG Reverse 
MAB85 Used in construction of pEG7S-BvgSEc ATCGTCTACCTGCGTCGACAGATTGTGCGC Forward 
MAB86 Used in construction of pEG7S-BvgSEc TCTGTCGACGCAGGTAGACGATCCAGCTCAGG Reverse 
MAB87 Used in construction of pEG7S-BvgSEc TGACGGATCCAGCTTCAGCCGGCCGT Forward 
MAB88 Used in construction of pEG7S-BvgSEc GGTCTTGGCCCGGTTAGAGTCTTCGGCG Reverse 
MAB89 Used in construction of pEG7S-BvgSEc TCTAACCGGGCCAAGACCACGTTCCTGG Forward 
MAB90 Used in construction of pEG7S-BvgSEc ATCGGAGCTCCGAGAACGGTTTGAACAGCTG Reverse 
MAB91 Used in construction of pEG7S-BvgS C607A and pEG7S-BvgS C607S TGACGGATCCAGCAGCGCTATCCCCAGG Forward 
MAB92 Used in construction of pEG7S-BvgS C607A AGGTACGCGTCATTCGCCAACAGCATGCGGCCTTCCT Reverse 
MAB93 Used in construction of pEG7S-BvgS C607A TTGGCGAATGACGCGTACCTCGACACCTTTGGCGTGACT Forward 
MAB94 Used in construction of pEG7S-BvgS C607A and pEG7S-BvgS C607S ATCGGAGCTCGGCGCCAGGTCGAATTTT Reverse 
MAB95 Used in construction of pEG7S-BvgS C607S AGGTACGCGTCATTAGACAACAGCATGCGGCCTTCCT Forward 
MAB96 Used in construction of pEG7S-BvgS C607S TTGTCTAATGACGCGTACCTCGACACCTTTGGCGTGACT Reverse 
MAB132 Used in construction of PfhaB-gfp GTACGAATTCCCGTGCGGGC Forward 
MAB133 Used in construction of PfhaB-gfp GTACAAGCTTCGACCAGCGAAGTGAAGTAATC Reverse 
MAB134 Used in construction of PptxA-gfp GTACGAATTCGCATACGTGTTGGCAACCG Forward 
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CHAPTER 4. TWO HIGH AFFINITY CYTOCHROME OXIDASES ARE REQUIRED 
FOR MAXIMAL COLONIZATION OF THE MAMMALIAN LOWER RESPIRATORY 
TRACT BY BORDETELLA BRONCHISEPTICA3 
Introduction 
Bordetella pertussis is the Gram-negative bacterium responsible for causing the severe 
respiratory illness pertussis, or whooping cough, in humans (1). Despite high rates of 
vaccination, pertussis has reemerged as an urgent global public health threat in recent years (2, 
3). Closely related to B. pertussis, Bordetella bronchiseptica can also cause severe respiratory 
illness, but in a wide range of mammals (4, 5). Despite differences in host range, B. pertussis and 
B. bronchiseptica use a similar set of virulence factors to colonize the mammalian respiratory 
tract. In both species the expression of almost all known virulence factor-encoding genes is 
controlled by BvgAS, a complex, two-component sensory transduction system (5–8). Our 
laboratory primarily studies B. bronchiseptica because its broad host range permits the use of 
natural host animal models to study the role of Bordetella virulence factors and their regulation 
in vivo (9, 10). In addition to regulating virulence, BvgAS differentially regulates the expression 
of hundreds of genes in Bordetella, allowing the bacteria to transition between three different 
phenotypic phases: the Bvg+ phase that is necessary for virulence in mammals (11); the Bvg– 
phase that in B. bronchiseptica is required for survival under nutrient-limiting conditions (11, 12) 
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and for interactions with non-mammalian hosts (13); and the Bvgi phase that has been 
hypothesized to be important for bacterial transmission (12, 14). 
The BvgAS system comprises two proteins. BvgS is a membrane-spanning sensor kinase 
with two, N-terminal, periplasmic Venus Flytrap domains (VFTs), followed by a transmembrane 
domain, a cytoplasmic Per-Arnt-Sim (PAS) domain, a histidine kinase (HK) domain, a receiver 
domain (REC), and a C-terminal histidine phosphotransfer (Hpt) domain (15). BvgA is a 
canonical response regulator with a N-terminal REC domain and a C-terminal helix-turn-helix 
(HTH) DNA binding domain (16, 17). When Bordetella is grown in the laboratory at 37˚C on 
Bordet-Gengou (BG) blood agar or in Stainer-Scholte (SS) broth, BvgS undergoes 
autophosphorylation and functions as a kinase (18–20). Subsequently, via a His-Asp-His 
phosphorelay, BvgS trans-phosphorylates BvgA (15, 18, 21). BvgA~P can then dimerize and 
bind DNA to promote or repress gene transcription (17, 22, 23). When BvgS is active (kinase 
activity) high levels of BvgA~P accumulate in the cell and the bacteria express the virulent Bvg+ 
phase, which is characterized by the expression of all known virulence factors (7). BvgS can also 
function as a phosphatase. When Bordetella is cultured in the presence of millimolar 
concentrations of nicotinic acid (NA) or magnesium sulfate (MgSO4), or at low temperature 
(25˚C) BvgS dephosphorylates BvgA, inactivating the regulator protein (15, 24–28). When 
levels of BvgA~P are depleted within the cell, the bacteria express the Bvg– phase, which is 
characterized by the expression genes required for bacterial survival in nutrient limited 
conditions and those encoding the flagella apparatus in B. bronchiseptica (11, 12, 29). When 
BvgA~P accumulates to intermediate levels within the cell, the bacteria express the Bvgi phase, 
which is characterized by maximal expression of the intermediate phase gene bipA (12, 22, 30, 
31). The transition from expressing the Bvg+ phase to expressing the Bvg– phase is termed 
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‘phenotypic modulation’. Although BvgS activity can be manipulated in the laboratory, the 
environmental signals that influence BvgS activity are unknown.  
It has been known for some time that the activity of BvgAS and expression of the Bvg+ 
phase is essential for Bordetella colonization of the mammalian respiratory tract (11, 18, 21, 24, 
32–34). Recently, we discovered that maintenance of BvgS kinase activity in the lower 
respiratory tract (LRT) requires the activity of another TCS called PlrSR (10). Furthermore, we 
have demonstrated that the PAS domain of BvgS is required for BvgS’s dependency on the 
PlrSR system specifically at this site of infection. It is unknown, however, by what mechanism 
the PlrSR system influences BvgS function in the LRT.    
PlrSR is a member of the NtrYX family of TCS, members of which are involved in 
sensing and responding to changes in redox status and anaerobiosis (35–37). In Brucella abortus 
and Neisseria gonorrhoeae, NtrYX systems control genes involved in bacterial respiration, such 
as those encoding high affinity cytochrome oxidases (HACOs), in response to low oxygen (37, 
38). Bordetella are strict aerobes and rely on cytochrome oxidases to convert oxygen into water 
as the terminal electron acceptor during respiration (39, 40). B. bronchiseptica contains seven 
gene loci predicted to encode cytochrome oxidases. Three of the cytochrome oxidases, one aa3-
type and two bo3-type, are predicted to have a low affinity for oxygen, while the remaining four, 
one cbb3-type and three bd-type, are predicted to have high affinity for oxygen (41). In the LRT, 
a potentially low oxygen environment, high affinity cytochrome oxidases (HACOs) may be 
required for Bordetella respiration to ensure efficient utilization of scare oxygen (42). Loss of 
HACOs within a low O2 environment would likely alter the redox status of the electron transport 
chain components within the bacterial membrane, including the redox reactive molecule 
ubiquinone. Interestingly, the BvgS PAS domain, which is required for BvgS’s dependency on 
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PlrSR in the LRT, contains a quinone binding perception motif [aliphatic-(X)3-H-(X)2,3-(L/T/S)] 
and it has been reported that BvgS kinase activity is sensitive to the redox state of ubiquinone 
(43, 44). Therefore, based on our work and the work of others, we hypothesize that PlrSR 
controls the expression of genes encoding HACOs, which are required for bacterial respiration 
and maintenance of BvgAS kinase activity in the LRT.  
Despite the large number of cytochrome oxidase-encoding loci maintained in the 
Bordetella genome, little is known about how they are regulated, how the encoded proteins 
contribute to the physiology of the bacteria, how the genes encoding cytochromes are regulated, 
or whether they are required for bacterial survival in the mammalian host. In vitro studies 
focused on understanding cytochrome c biogenesis in B. pertussis showed that cytochrome c and 
cytochrome c-dependent oxidases (the aa3-type and cbb3-type cytochromes) are dispensable for 
bacterial growth in the laboratory, indicating that quinol dependent cytochromes (bo3-type and 
bd-type cytochromes) can sustain bacterial respiration under these conditions (39, 45). 
Additional studies indicate that the cbb3-type cytochrome is likely non-functional in B. pertussis 
as mutations in the genes encoding aa3-type cytochrome subunits render B. pertussis oxidase 
negative (46). Although, multiple transcription analyses have been performed for Bordetella 
grown in various conditions, these studies provide little evidence of how the cytochrome oxidase 
operons are regulated (7, 47, 48). In this study, we used transcriptional and recombinase-based 
reporters to characterize the expression profile of HACO encoding genes in vitro and in vivo and 
to determine if HACO expression depends on PlrSR. We also characterized B. bronchiseptica 
mutants with deletions in HACO genes in a mouse model of colonization to determine the 
importance of HACOs for persistence of Bordetella and for the maintenance of BvgAS activity 




High-affinity cytochrome oxidase loci are differentially regulated in ambient air in vitro  
To characterize the expression profile of each putative high affinity cytochrome oxidase 
(HACO) operon in vitro, we constructed transcriptional reporters with the predicted promoters of 
each HACO gene cluster driving the expression of lacZ. We evaluated HACO promoter activity 
in the wild-type B. bronchiseptica strain RB50 (WT) compared to promoter activity in two 
BvgAS phase-locked mutants (BvgSC and ∆bvgS) and a plrS deletion mutant (∆plrS) to 
determine if any HACO genes are transcriptionally regulated by BvgAS or PlrSR.  
When grown under Bvg+ phase conditions (37˚C) in ambient air, the activity of two 
HACO promoters, BB4498-BB4497 (cydAB1) and BB1238-BB239 (cydAB2), were significantly 
increased in the Bvg– phase-locked mutant (∆bvgS) compared to the Bvg+ phase-locked mutant 
(BvgSC) or wild-type RB50 (WT) (Fig. 4.1A and 4.1B), indicating that these HACO genes are 
repressed by BvgAS under these conditions. Expression of cydAB1 and cydAB2 was also 
significantly greater in WT and BvgSC compared to the wild-type empty vector control (WT-
EV), suggesting that these genes may also be regulated via a mechanism independent of BvgAS 
(Fig. 4.1A and 4.1B). The BB3329-BB326 (ccoNOQP) promoter was highly active in WT grown 
under Bvg+ phase conditions (Fig. 4.1D), however, expression of ccoNOQP did not dependent 
on BvgAS or PlrSR activity as there was no difference in ccoNOQP transcription between 
BvgAS phase-locked strains, a ∆plrS mutant, and WT (Fig. 4.1D). The BB4012-BB4011 
(cydAB3) promoter was expressed in WT at very low levels, suggesting these genes are not 
expressed under Bvg+ phase growth conditions and are not regulated by BvgAS or PlrSR in vitro 
(Fig. 4.1C). Overall, these data demonstrate that putative HACO operons are differentially 
regulated in B. bronchiseptica and that BvgAS has the ability to influence the transcription of 
two HACO loci in ambient air conditions in vitro.   
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B. bronchiseptica requires high-affinity cytochrome oxidases to robustly colonize the 
mammalian lower respiratory tract   
To determine if high affinity cytochrome oxidases (HACO) contribute to Bordetella 
colonization of the respiratory tract, we engineered strains of B. bronchiseptica with deletions in 
each HACO operon. We also constructed a strain lacking the genes encoding all three bd-type 
HACOs and a strain lacking all HACOs, to determine if any HACOs may be functionally 
redundant. We then tested these strains in a mouse model of colonization.  
Strains lacking a single HACO or multiple HACOs colonized the murine nasal cavity 
(NC) similar to WT (Fig. 4.2A and 4.3A), suggesting that HACOs are not required for 
Bordetella colonization of the upper respiratory tract. In the lower respiratory tract (LRT), the 
∆cydAB3 mutant was significantly attenuated in colonization of the trachea compared to WT and 
exhibited reduced colonization in the lungs, indicating that this cytochrome is required for robust 
bacteria colonization of the LRT (Fig. 4.2B and 4.2C). In vitro, under Bvg+ phase conditions, the 
cydAB3 promoter was not active in WT, however the essentiality of this gene cluster in vivo, 
suggests that cydAB3 operon may only be expressed during colonization of the LRT. Similarly, 
the ∆cydAB1 mutant also exhibited reduced colonization of the LRT compared to WT, indicating 
that this cytochrome may also contribute to Bordetella survival in the mammalian host (Fig. 4.2B 
and 4.2C). All other single HACO deletion strains were able to colonize the LRT similar to WT 
(Fig. 4.2B and 4.2C).  
B. bronchiseptica strains lacking genes encoding all bd-type cytochromes (∆cydAB123) 
or all four HACOs (∆all HACOs) were attenuated in the LRT compared to WT (Fig. 4.3B and 
4.3C). Although ∆cydAB123 and ∆all HACOs exhibited very similar colonization kinetics, only 
the ∆all HACOs mutant was significantly defective for colonization compared to WT, suggesting 
that the cbb3- type HACO (ccoNOQP) contributes to Bordetella colonization in the LRT. 
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However, attenuation was not observed for the single cooNOQP deletion strain, suggesting that 
the slight contribution of this cytochrome to colonization of the LRT may only occur when all 
other HACOs are non-functional. Compared to the ∆cydAB1 and ∆cydAB3 single deletion 
mutants, ∆cydAB123 and ∆all HACOs were similarly attenuated in the LRT, suggesting that 
HACOs are not functionally redundant in B. bronchiseptica when in the LRT.  Overall, these 
data indicate that the cytochromes cydAB1 (BB4498-BB4497) and cydAB3 (BB4012-4011) 
likely contribute to robust colonization of the lower mammalian respiratory tract by B. 
bronchiseptica.  
Maintenance of BvgAS kinase activity does not depend on bd-type cytochrome oxidases in 
vivo 
Based on our model, we predict that the activity of HACOs may influence the activity of 
the BvgAS system. BvgAS activation is essential for Bordetella colonization and our data 
indicate that cydAB1 (BB4498-BB4497) and cydAB3 (BB4012-4011) are required for robust 
colonization of the LRT, therefore we analyzed BvgAS activity in ∆cydAB1, ∆cydAB3, and 
∆cydAB123, using the plasmid reporter, pGFLIP-PflaA. pGFLIP-PflaA is a recombinase-based 
reporter that indicates whether the bacteria have expressed the flaA gene, and hence the Bvg– 
phase, at any time during the course of the experiment (49). Expression of flaA results in a 
conversion of the bacteria from GFP+ and Kmr to GFP– and Kms (REF). As expected, all HACO 
deletion strains with pGFLIP-PflaA colonized the nasal cavity similar to WT (Fig. 4.4A). In 
contrast to our previous experiment, there was no significant difference in colonization of the 
LRT by the HACO single deletion mutants compared to WT (Fig. 4.4B), however ∆cydAB123 
was significantly attenuated in the lungs (Fig. 4.4B and 4.4C). For WT and all HACO mutants, 
very few, if any, GFP negative colonies were recovered from the mouse respiratory tract (Fig. 
4.4D, 4.4E, and 4.4F), indicating that the flaA promoter was not expressed and all bacteria 
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remained in the Bvg+ phase during the experiment. Overall, these data demonstrate that 
maintenance of BvgS kinase activity does not depend on the function of bd-type HACOs during 
Bordetella respiratory tract colonization.    
Although required for robust colonization in vivo, the BB4012-BB4011 (cydAB3) promoter 
is inactive during colonization of the murine respiratory tract 
We have shown that in B. bronchiseptica, the cydAB3 cytochrome operon is not 
expressed in vitro, however, this cytochrome is required for robust colonization of the LRT, 
suggesting that the genes encoding cydAB3 are only expressed during colonization of the LRT. 
Using the pGFLIP reporter system, we aimed to determine if the cydAB3 promoter is active in 
vivo and if the PlrSR system regulates the expression of this gene cluster in the LRT. The 
putative cydAB3 promoter was engineered to drive expression of the flp recombinase in pGFLIP 
to create the plasmid reporter, pGFLIP-PcydAB3. This reporter was introduced into WT and a plrS 
deletion strain (∆plrS).  
As expected, and shown previously (10, 35), WT and ∆plrS with the pGFLIP-PcydAB3 
reporter colonized the NC similarly, while ∆plrS was rapidly cleared from the LRT (Fig. 4.5A 
and 4.5B). Very few, if any, WT bacteria were recovered from the NC and LRT were GFP–, 
indicating that the PcydAB3 was not active in WT during respiratory tract colonization (Fig. 4.5C  
and 4.5D). Similarly, very few GFP– ∆plrS bacteria were recovered from the upper and lower 
respiratory tract. Together, these data suggest that the cydAB3 promoter is not active during 
infection and is not regulated by the PlrSR system. These results contradict our previous data 
indicating that the cydAB3 cytochrome is required for Bordetella colonization in the LRT, 
suggesting that the cydAB genes are expressed during infection. Therefore, it is possible that the 
segment of DNA used to drive transcription of flp recombinase in pGFLIP-PcydAB3 does not 
contain the complete promoter region that regulates the cydAB3 operon or that the activity of 
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PcydAB3 is insufficient to adequately drive expression of the flp recombinase in order to resolve 
the gfp from the pGFLIP reporter.  
Discussion 
As obligate aerobes, pathogenic Bordetella rely on cytochrome oxidases to reduce 
oxygen into water as the final step in electron transport-coupled oxidative phosphorylation. 
Although Bordetella maintains many loci encoding putative cytochrome oxidase complexes 
within its genome, it is unknown how these proteins contribute to the bacteria’s physiology and 
what role, if any, they may play in bacterial virulence. We became interested in understanding 
more about the requirement of cytochrome oxidases for Bordetella virulence and how they are 
regulated, in hopes of determining if HACOs govern the link between PlrSR and the master 
regulator of virulence, BvgAS, during bacterial colonization of the mammalian LRT. While our 
results indicate that some of the HACOs encoded in the B. bronchiseptica genome are required 
for robust bacterial colonization of the trachea and lungs, we found no evidence that BvgAS 
activity was influenced by the absence of HACOs and it remains to be determined if PlrSR 
regulates the expression of HACO encoding genes in vivo.  
Out of the four HACO loci that B. bronchiseptica encodes, two are required for robust 
colonization specifically in the LRT: (BB4498-BB4497 (cydAB1) and BB4012-BB4011 
(cydAB3)). No HACOs were required for B. bronchiseptica colonization of the upper respiratory 
tract. Our results indicate that CydAB1 and CydAB3 are not functionally redundant, and without 
either cytochrome approximately 90% of the bacteria are cleared from the LRT compared to 
WT. Interestingly, bacteria lacking both cytochromes (CydAB1 and CydAB3, as well as 
CydAB2, ∆cydAB123) did not exhibit a cumulative reduction in bacterial burden compared to 
the single deletion strains, indicating that perhaps the requirement of each cytochrome is 
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restricted to a distinct lower airway niche or to a specific time during the establishment of 
infection. In support of this idea, respiratory heterogeneity within a bacterial population has been 
implicated as being important for biofilm formation and colonization of the host by 
uropathogenic E. coli and it is possible that a similar phenomenon could explain the phenotypes 
we have observed for Bordetella colonization in the LRT (50).  
While HACOs contribute to Bordetella survival in the LRT, a significant number of 
bacteria, lacking all functional HACOs (∆all HACOs), were recovered from the trachea and 
lungs, suggesting that other types of cytochrome oxidases (most likely the low affinity 
cytochrome oxidases (LACOs)) may also play a role in Bordetella colonization of the trachea 
and lungs. For example, bacteria still present in the lungs after 3 days of colonization may be 
localized within an environment that does not require the use of HACOs for bacterial respiration 
but instead depends on LACOs. To more completely understand how cytochrome oxidases 
contribute to Bordetella colonization of the mammalian host, we have expanded the scope of our 
studies to determine if LACOs are also important for LRT colonization and are interested in 
determining whether bacterial localization within the LRT influences the necessity of certain 
types of cytochrome oxidases.    
  CydAB1 and CydAB3 (BB4498-BB4497 (cydAB1) and BB4012-BB4011 (cydAB3)) are 
bd-type cytochrome oxidases. Bd cytochrome oxidases are prokaryotic-specific respiratory 
quinol:O2 oxidoreductases, which are unrelated to the extensively studied family of heme-copper 
oxidases and use quinols as a physiological reducing substrate (51–53). Many pathogenic 
bacteria produce bd-type cytochrome oxidases and virulence has been linked with the production 
of this particular type of oxidase (37, 50, 54–57). In addition to being critical for bacterial 
respiration and maintenance of the proton motive force, often in environments of low oxygen, it 
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has recently become appreciated that bd-type cytochrome oxidases are also important for defense 
against the host immune response and oxidative and nitrosative stresses (50, 53, 56–62). Mild to 
severe leukocytosis, or an influx of circulating white blood cells, is often associated with 
Bordetella infection. Although Bordetella has an arsenal of toxins to evade immune cell 
clearance and to prevent reactive oxygen species (ROS) production from these cell types, it is 
possible that the production of bd-type cytochrome oxidases helps the bacteria resist oxidative 
stress during infection.  
To date, our data suggest that maintenance of BvgS kinase activity does not depend on 
the activity of bd-type HACOs during respiratory tract colonization. Using pGFLIP-PflaA, we 
demonstrated that the flaA promoter was not activated in the triple bd-type cytochrome deletion 
mutant (∆cydAB123) during respiratory tract colonization, indicating that the bacteria did not 
modulate to the Bvg– phase while in the host. However, by only using pGFLIP-PflaA, we cannot 
rule out that BvgS kinase activity was slightly reduced in the cytochrome mutants, albeit not 
enough to fully modulate the bacteria to the Bvg– phase. To confirm BvgS kinase activity is 
unaffected by the lack of HACO production, we plan to use the pGFLIP-PptxA reporter to assess 
BvgS activity in our HACO deletion strains. The ptx promoter, which drives the expression of 
genes encoding pertussis toxin and its export system in B. pertussis, contains low affinity 
BvgA~P binding sites and requires high levels of BvgA~P within the cell for activation. 
Therefore, use of the pGFLIP-PptxA reporter would allow us to discern a minute drop in BvgA~P 
levels in the cell and hence slight changes in BvgS kinase activity. We are also interested in 
determining if BvgAS activity is influenced by the activity of LACOs since we hypothesize these 
proteins may be important for Bordetella LRT colonization and we plan to use both 
recombinase-based reporters to evaluate BvgAS activity in strains lack LACOs.  
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Based on our in vitro transcriptional analyses, no HACO loci were regulated by PlrSR. 
However, it is important to note that our studies have been limited to the evaluation of bacteria 
grown in the laboratory in ambient air. We do not believe these growth conditions accurately 
mimic those encountered in the LRT; an environment in which B. bronchiseptica lacking PlrS is 
severely attenuated. A ∆plrS mutant exhibits no discernable phenotype compared to wild-type B. 
bronchiseptica when grown in vitro. Therefore, we plan to continue our analysis of cytochrome 
oxidase gene expression in bacteria grown in vitro with low oxygen and during respiratory tract 
colonization to understand which cytochrome oxidases are important under these conditions and 
if they are regulated by PlrSR.  
Although we have demonstrated that some HACOs contribute to robust colonization of 
the LRT by Bordetella, our data indicate that additional types of cytochromes are required by the 
bacteria in this environment. Thus far, we have found no evidence that BvgAS activity is 
significantly affected by the absence of HACOs or that PlrSR regulates the expression of HACO 
encoding genes. However, many questions remain and we plan to expand the scope of our 
studies to evaluate whether LACOs are required for bacterial colonization of the LRT and to 
confirm that BvgS kinase activity is not influenced by cytochromes oxidase activity in vivo. 
Regardless of our findings, the work presented in this chapter creates a strong foundation for 
further investigation into the importance of cytochrome oxidases for Bordetella physiology and 
pathogenesis in the mammalian host.      
Materials and Methods 
Bacterial strains, plasmids, and growth conditions 
All bacterial strains and plasmids used in this study are listed in Table 1. Escherichia coli 
strains were grown using Lysogeny broth (LB) or agar at 37C. B. bronchiseptica strains were 
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grown on Bordet-Gengou (BG) agar supplemented with 7.5% defribinated sheep blood or in 
Stainer-Scholte (SS) broth supplemented with SS supplement at 37°C. As needed, media was 
supplemented with ampicillin (Amp; 100 g/mL), streptomycin (Sm; 20 g/mL), gentamicin 
(Gm; 30 g/mL), kanamycin (Km; E.coli at 50 g/mL or B. bronchiseptica at 125 g/mL), or 
diaminopimelic acid (DAP; 300 g/mL).   
Construction of high-affinity cytochrome oxidase lacZ transcriptional reporters  
To construct lacZ transcriptional reporters for all high-affinity cytochrome oxidase 
operons, each putative promoter was amplified by PCR from B. bronchiseptica RB50, using 
primers listed in Table 2. PCR products were digested and cloned into the pUC-lacZ plasmid 
using EcoRI and HindIII restriction sites. The insert was then sequenced for verification. The 
resulting plasmids were then introduced into WT, BvgSC, ∆bvgS, and ∆plrS strains using tri-
parental mating with conjugative RHO3. Reporter delivery to the Tn7 site was confirmed by 
PCR in each strain. 
Transcriptional analysis of high-affinity cytochrome oxidase encoding genes in vitro 
To analyze expression of the HACO genes under Bvg+ phase conditions a beta-
galactosidase assay was used. Strains were grown on BG-blood agar supplemented with 
kanamycin at 37 °C until colonies formed. Approximately 3-4 single colonies were used to 
inoculate liquid SS media with kanamycin, which were grown overnight for ~18 h at 37 °C in 
ambient air on a roller. One-hundred microliters of each culture was diluted using 1x Z-Buffer 
with freshly added 2-Mercaptoethanol (-ME) to a 1mL total volume in a clean centrifuge tube. 
Diluted samples were vortexed and 250 microliters (L) of each sample was transferred to a 96-
well, flat bottom, polystyrene plate, and the OD600 was measured on a Perkin-Elmer Victor3 
1420 Multi-label plate reader. Subsequently, 50 L of chloroform and 10 L of 0.1% SDS were 
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added to each of the remaining 750 L diluted samples to permeabilize the bacterial cells. 
Samples were vortexed for ~ 15 seconds and allowed to settle until the organic and inorganic 
layers were clearly separated. In a 96-well, flat bottom, polystyrene plate, 50 L of each 
permeabilized cell sample, 150 L of fresh 1x Z-Buffer, and 50 L of ONPG at a concentration 
of 4 mg/mL were added to wells in triplicate. OD420 was then measured every minute for 20 
minutes on a Perkin-Elmer Victor3 1420 Multi-label plate reader for each sample. -gal activity 
units were determined for each sample using the equation, -gal units = (∆OD420)/ 
((∆T)*(OD600)*(V)) where ∆OD420 equals the difference between OD420 readings at Time 2 
(T2)- Time 1(T1) (Note: Values must be within the linear range of the 420 absorbance curve), 
∆T equals Time 2 (T2)- Time 1(T1) in minutes, V equals the volume of culture assayed in 
milliliters (Amount of permeabilized cells added to each 96 well), and OD600 equals the optical 
density of each diluted sample. Cultures were tested in duplicate and the experiment was 
repeated three times. -gal activity units were averaged across all replicates. 
Construction of B. bronchiseptica high-affinity cytochrome oxidase deletion strains  
DNA manipulation and cloning were performed according to standard molecular cloning 
methods. All restriction enzymes and DNA ligase were obtained from New England Bio Labs. 
High-fidelity PFU Ultra II DNA polymerase was used for construction of all allelic exchange 
vectors used in this study. GoTaq DNA polymerase was used for screening purposes during 
plasmid and strain construction. All enzymes were used according to the manufacturer’s 
instructions. The primers used for creating deletions are listed in Table 2. All primers were 
synthesized by Eton Biosciences and purified using a standard desalting method.   
Allelic exchange plasmids were generated to delete each high affinity cytochrome 
oxidase operon. Primers were used to generate an approximately 1 kb DNA fragment containing 
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3 codons from the beginning of the first gene within the operon and 3 codons from the end of the 
last gene within the operon, flanked by homologous sequences (~500 bp each) corresponding to 
the regions 5’ and 3’ to the desired deletion. Primers used to generate the most 5’ and 3’ ends of 
the DNA fragments for each mutant were designed to include a BamHI restriction site at the 5’ 
end and a SacI restriction at the 3’ end, which were used to clone the DNA fragments into the 
allelic exchange plasmid pEG7S (63). Standard methods were then used to deliver these 
plasmids to RB50 by conjugation using RHO3 cells. Double homologous recombination events 
that introduced the desired mutation into the chromosome were selected for using 15% sucrose. 
Sanger sequencing was used to verify deletion of each HACO operon. Allelic exchange was 
repeatedly performed using a different deletion plasmid each time to make the triple and 
quadruple HACO deletion strains. The pGFLIP-PflaA reporter was introduced into each mutant 
strain, using tri-parental mating with conjugative RHO3 and integration of the reporter on to the 
chromosome at the attTn7 site was verified using PCR.  
Bacterial colonization of the mouse respiratory tract 
Six-week-old female BALB/cJ mice from Jackson Laboratories (Bar Harbor, ME) were 
inoculated intra-nasally with 7.5 x 104 cfu B. bronchiseptica in 50 μL of phosphate-buffered 
saline (PBS). For all time points, nasal cavity, tracheal tissue, and right lung lobes were 
harvested; tissues were homogenized, and the number of cfu was determined by plating dilutions 
of tissue homogenates on BG blood agar supplemented with streptomycin.  
Evaluation of B. bronchiseptica modulation in vivo 
Bacteria were cultured overnight at 37 °C in SS media with streptomycin, kanamycin, 
and gentamicin to maintain bacteria in the Bvg+ phase (20). Six-week-old female BALB/c mice 
from Jackson Laboratories (Bar Harbor, ME) were inoculated intra-nasally with 7.5 × 104 cfu of 
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B. bronchiseptica strains (containing the pGFLIP-PflaA reporter) in 50 μL of 1 X DPBS. At each 
time point reported, nasal cavity, tracheal tissue, and right lung lobes were harvested and 
homogenized in 1 X DPBS using a mini-bead beater. Dilutions of the tissue homogenates were 
then plated on BG-blood agar, supplemented with streptomycin and gentamicin, and grown at 
37C for 72 h. White light (to enumerate total cfu) and blue light (to enumerate GFP+ colonies) 
images of each plate were captured using a G:Box Imaging System (Syngene). Total cfu and 
GFP positive colonies were enumerated using the colony analysis protocol of the GeneTools 
Software package (Syngene). The total number of GFP negative colonies was calculated by 
subtracting the number of GFP positive colonies from the total number of colonies isolated. The 
percent GFP negative colonies was calculated by determining the ratio of GFP negative colonies 
to the total number of colonies isolated. 
Construction of pGFLIP-PcydAB3 reporter 
To construct pGFLIP-PcydAB3, the putative promoter (-1 to -179bp) driving expression of 
cydAB3 (BB4012-BB4011) was amplified by PCR from B. bronchiseptica RB50, using primers 
listed in Table 2. PCR products were digested and cloned into the pGFLIP plasmid using SacI 
and KpnI restriction sites. The construct was then sequenced for verification. The resulting 
plasmid was introduced into WT and ∆plrS strains using tri-parental mating with conjugative 
RHO3. Reporter delivery to the Tn7 site was confirmed by PCR. 
Evaluation of cydAB3 expression in vivo 
Bacteria were cultured overnight at 37 °C in SS media with streptomycin and kanamycin 
(REF). Six-week-old female BALB/c mice from Jackson Laboratories (Bar Harbor, ME) were 
inoculated intra-nasally with 7.5 × 104 cfu of B. bronchiseptica strains (containing the pGFLIP-
PcydAB3 reporter) in 50 μL of 1 X DPBS. At each time point reported, nasal cavity and right 
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lung lobes were harvested and homogenized in 1 X DPBS using a mini-bead beater. Dilutions of 
the tissue homogenates were plated on BG-blood agar, supplemented with streptomycin, and 
grown at 37C for 72 h. White light (to enumerate total cfu) and blue light (to enumerate GFP+ 
colonies) images of each plate were captured using a G:Box Imaging System (Syngene). Total 
cfu and GFP positive colonies were enumerated using the colony analysis protocol of the 
GeneTools Software package (Syngene). The total number of GFP negative colonies was 
calculated by subtracting the number of GFP positive colonies from the total number of colonies 
isolated. The percent GFP negative colonies was calculated by determining the ratio of GFP 
negative colonies to the total number of colonies isolated. 
Ethics statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health (64). All animals 
were properly anesthetized for inoculations, monitored regularly, and killed when moribund. 
Efforts were made to minimize suffering. Our protocol was approved by the University of North 
Carolina Institutional Animal Care and Use Committee (Protocol ID: 16-246).  
Statistical analysis 
Statistical analysis was performed using Prism 7.0d software from GraphPad Software. 
Statistical significance was determined using a Kruskal-Wallis test with multiple comparisons. P 








Figure 4.1. In vitro, BvgS influences the expression of high affinity cytochrome oxidase 
encoding genes in B. bronchiseptica. Transcriptional analysis of putative HACO promoter 
activity in wild-type (WT), BvgSC, ∆bvgS, and ∆plrS strains of B. bronchiseptica using the lacZ-
based reporters. WT-EV and ∆bvgS-EV contain empty reporters with no promoter driving lacZ 
expression as controls. All strains were cultured in Stainer Scholte (SS) broth and ambient air at 
37 °C with agitation (Bvg+ growth conditions). (A) Activity of the putative promoter for genes 
BB4498-97 (cydAB1). (B) Activity of the putative promoter for genes BB1238-39 (cydAB2). (C) 
Activity of the putative promoter for genes BB4012-11 (cydAB3). (D) Activity of the putative 
promoter for genes BB3329-26 (ccoNOQP). Colored bars represent the mean beta-gal activity 
units per cell calculated from triplicate experiments. Error bars represent the standard deviation 
of beta-gal activity units per cell for each data set. Statistical significance (Kruskal-Wallis Test 
with multiple comparison, P < 0.05) between strains is indicated with * (P < 0.05), ** (P < 0.01), 
















Figure 4.2. Two bd-type high-affinity cytochrome oxidases contribute to B. bronchiseptica 
colonization of the trachea in mice. Colonization of the (A) nasal cavity, (B) trachea, and (C) 
right lung tissue in female BALB/cJ mice by wild type (WT; black circles), ∆cydAB1 (blue 
squares), ∆cydAB2 (red squares), ∆cydAB3 (green diamonds), and ∆ccoNOQP (purple triangles) 
strains on days 0, 1, 3, and 7 post-inoculation. Mice were inoculated with 7.5 x104 cfu via the 
external nares. Each symbol represents a single animal, with the mean colonization depicted as 
short horizontal bars. Statistical significance (Kruskal-Wallis test and Dunn’s multiple 









Figure 4.3. Without high-affinity cytochrome oxidases B. bronchiseptica is significantly 
attenuated for colonization of the trachea and LRT in mice. Colonization of the (A) nasal 
cavity, (B) trachea, and (C) right lung tissue in female BALB/cJ mice by wild type (WT; black 
circles), ∆cydAB123 (orange hexagons), and ∆all HACOs (yellow triangles) strains on days 0, 1, 
3, and 7 post-inoculation. Mice were inoculated with 7.5 x104 cfu via the external nares. Each 
symbol represents a single animal, with the mean colonization depicted as short horizontal bars. 
Statistical significance (Kruskal-Wallis test and Dunn’s multiple comparisons test, P < 0.05) is 











Figure 4.4. Maintenance of BvgS kinase activity does not require bd-type high-affinity 
cytochrome oxidases during respiratory tract colonization of mice. Colonization of the (A) 
nasal cavity, (B) trachea, and (C) right lung tissue in female BALB/cJ mice by wild type (WT; 
black circles), ∆cydAB1 (red squares), ∆cydAB3 (green triangles), and ∆cydAB123 (blue 
diamonds) strains on days 0, 1, and 3 post-inoculation. All strains contain the plasmid reporter, 
pGFLIP-PflaA. Mice were inoculated with 7.5 x10
4 cfu via the external nares. Each symbol 
represents a single animal, with the mean colonization depicted as short horizontal bars. 
Percentage of GFP negative (% GFP–) bacteria recovered from the (D) nasal cavity, (E) trachea, 
and (F) right lung. GFP negativity indicates bacterial modulation and loss of BvgS kinase 
activity. Statistical significance (Kruskal-Wallis test and Dunn’s multiple comparisons test, P < 










Figure 4.5. The cydAB3 promoter is not active during respiratory tract colonization.  
Colonization of the (A) nasal cavity and (B) right lung tissue in female BALB/cJ mice by wild 
type (WT; black circles) and ∆plrS (red triangles) strains on days 0, 1, and 3 post-inoculation. 
All strains contain the plasmid reporter, pGFLIP-PcydAB3. Mice were inoculated with 7.5 x10
4 cfu 
via the external nares. Each symbol represents a single animal, with the mean colonization 
depicted as short horizontal bars. Percentage of GFP negative (% GFP–) bacteria recovered from 
the (C) nasal cavity and (D) right lung. GFP negativity indicates the cydAB3 promoter was active 
in the bacteria. Statistical significance (Kruskal-Wallis test and Dunn’s multiple comparisons 













Table 1. Bacterial Strains and Plasmids Used in this Study 
Bacterial Strain or Plasmid Description Reference 
E.coli Strains   
DH5α Molecular cloning strain  GIBCO BRL 
RHO3 Conjugation strain; Kms Δasd ΔaphA, DAP auxotroph  (65) 
B. bronchiseptica Strains   
RB50 (WT) Wild-type B. bronchiseptica strain; Smr (11) 
BvgSC (RB53) RB50 containing the bvgS R570H point mutation; Smr (11) 
∆bvgS (RB54) RB50 containing an in-frame deletion of bvgS; Smr (11) 
∆plrS RB50 containing an in-frame deletion of plrS; Smr (35) 
∆cydAB1 RB50 containing an in-frame deletion of genes BB4498-BB4497; Smr This Study 
∆cydAB2 RB50 containing an in-frame deletion of genes BB1238-BB1239; Smr This Study 
∆cydAB3 RB50 containing an in-frame deletion of genes BB4012-BB4011; Smr This Study 
∆ccoNOQP RB50 containing an in-frame deletion of genes BB3329-BB3326; Smr This Study 
∆cydAB123 RB50 containing an in-frame deletion of genes BB4498-BB4497, BB1238-BB1239, and BB4012-BB4011; Smr This Study 
∆all HACOs 
RB50 containing an in-frame deletion of genes BB4498-BB4497, BB1238-BB1239, BB4012-BB4011, and BB3329-
BB3326; Smr 
This Study 
Plasmids   
pEG7S 
Suicide plasmid conferring sucrose sensitivity when integrated into the B. bronchiseptica chromosome, used for allelic 
exchange mutagenesis; Gmr 
(12) 
pTNS3 attTn7 transposase expression vector containing tnsABCD; Ampr (65) 
pGFLIP-PflaA  pGFLIP with flp recombinase driven by the RB50 flaA promoter; Ampr, Kmr  (49) 
pGFLIP-PcydAB3 pGFLIP with flp recombinase driven by the putative RB50 cydAB3 promoter (BB4012-BB4011); Ampr, Kmr This Study 
pUC-lacZ attTn7 site-specific integration vector containing lacZ; Kmr (22) 
pUC-lacZ-cydAB1 pUC-lacZ with lacZ driven by the putative promoter for BB4498-BB4497; Kmr This Study 
pUC-lacZ-cydAB2 pUC-lacZ with lacZ driven by the putative promoter for BB1238-BB1239; Kmr This Study 
pUC-lacZ-cydAB3 pUC-lacZ with lacZ driven by the putative promoter for BB4012-BB4011; Kmr This Study 
pUC-lacZ-ccoNOQP pUC-lacZ with lacZ driven by the putative promoter for BB3329-BB3326; Kmr This Study 
pEG7S-∆cydAB1 
pEG7S plasmid containing a ~1 kb DNA fragment encoding an in-frame deletion of BB4498-BB4497 situated between 5’ 
and 3’ homologous sequences (500 bp each) that correspond to sequence flanking BB4498-BB4497 in RB50 bvgS 
This Study 
pEG7S-∆cydAB2 
pEG7S plasmid containing a ~1 kb DNA fragment encoding an in-frame deletion of BB1238-BB1239 situated between 
5’ and 3’ homologous sequences (500 bp each) that correspond to sequence flanking BB1238-BB1239 in RB50 bvgS 
This Study 
pEG7S-∆cydAB3 
pEG7S plasmid containing a ~1 kb DNA fragment encoding an in-frame deletion of BB4012-BB4011 situated between 5’ 
and 3’ homologous sequences (500 bp each) that correspond to sequence flanking BB4012-BB4011 in RB50 bvgS 
This Study 
pEG7S-∆ccoNOQP 
pEG7S plasmid containing a ~1 kb DNA fragment encoding an in-frame deletion of BB3329-BB3326 situated between 









Table 4.S2. Primers Used in this Study 
 






MAB97 Construction of the pUC-lacZ-cydAB1 Transcription Reporter ACTGGAATTCGGAGCTGATCGAGCTGTCCAC Forward 
MAB98 Construction of the pUC-lacZ-cydAB1 Transcription Reporter CAGTAAGCTTGAGACGCTCCCAGACGGTAGA Reverse 
MAB99 Construction of the pUC-lacZ-cydAB2 Transcription Reporter ACTGGAATTCAGGCACCATGCCACCGT Forward 
MAB100 Construction of the pUC-lacZ-cydAB2 Transcription Reporter CAGTAAGCTTTGAATCCGAACTGAATCCGG Reverse 
MAB101 Construction of the pUC-lacZ-cydAB3 Transcription Reporter CAGTGAATCCTGCCGGCCCACAGTTT Reverse 
MAB102 Construction of the pUC-lacZ-cydAB3 Transcription Reporter AGCTAAGCTTTAGAGCCTGTTTCCGGCAT Forward 
MAB103 Construction of the pUC-lacZ-ccoNOQP Transcription Reporter AGCTAAGCTTACACCACAGTCATGATGGCG Forward  
MAB104 Construction of the pUC-lacZ-ccoNOQP Transcription Reporter CAGTGAATTCCCGCGATATTGCGCGAT Reverse 
MAB57 Construction of the pEG7S-∆cydAB1 (Upstream Fragment) AGTCGAGCTCTTTTCGCGTTCCAACGTCA Forward 
MAB58 Construction of the pEG7S-∆cydAB1 (Upstream Fragment) ACTGGCTCCTGATCAGTACGAAGCCGACATGGCCTCC Reverse 
MAB59 Construction of the pEG7S-∆cydAB1 (Downstream Fragment) GGGAGGCCATGTCGGCTTCGTACTGATCAGGAGCCAGTCAT Forward 
MAB60 Construction of the pEG7S-∆cydAB1 (Downstream Fragment) TGACGGATCCAACGCCTCGCGCACCT Reverse 
MAB109 Construction of the pEG7S-∆cydAB2 (Upstream Fragment) GCCTCCTCAGTGATAACTCATCATGTGTGGCTCCC Reverse 
MAB110 Construction of the pEG7S-∆cydAB2 (Upstream Fragment) TGACGGATCCGTCAGCACGAACAGCGACG Forward 
MAB111 Construction of the pEG7S-∆cydAB2 (Downstream Fragment) CATGATGAGTTATCACTGAGGAGGCCGCC Reverse 
MAB112 Construction of the pEG7S-∆cydAB2 (Downstream Fragment) ATCGGAGCTCGCATGGTCAGCTGCAGCA Forward 
MAB113 Construction of the pEG7S-∆cydAB3 (Downstream Fragment) CGAACGGTAGGCTTGCAACAGTGTTTCCG Forward 
MAB114 Construction of the pEG7S-∆cydAB3 (Downstream Fragment) ATCGGAGCTCGCGAACTCGTACATGAATTCGAA Reverse 
MAB115 Construction of the pEG7S-∆cydAB3 (Upsteam Fragment) CTGTTGCAAGCCTACCGTTCGGTGTTCGGC Reverse 
MAB116 Construction of the pEG7S-∆cydAB3 (Upstream Fragment) TGACGGATCCGACCAGTTCATCGGCTTCG Forward 
MAB117 Construction of the pEG7S-∆ccoNOQP (Downstream Fragment) GCAGTTTGATCTGATCGTTCATCAGCCATCCCC Forward 
MAB118 Construction of the pEG7S-∆ccoNOQP (Downstream Fragment) ATCGGAGCTCCCTGGCACCTGCTCATGA Reverse 
MAB119 Construction of the pEG7S-∆ccoNOQP (Upstream Fragment) TGATGAACGATCAGATCAAACTGCTGTCGGC Reverse 
MAB120 Construction of the pEG7S-∆ccoNOQP (Upstream Fragment) TGACGGATCCACAGCACCAGCCCGAACA Forward 
MAB172 Introducing the PcydAB3 promoter into pGFLIP for in vivo analysis GTACGAGCTCTGCCGGCCCACAGTTTGC Forward 
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CHAPTER 5. DISCUSSION 
For many years, dogma in the Bordetella field has considered the BvgAS system the 
‘master regulator of virulence’, regulating the expression of all known protein virulence factor-
encoding genes and three unique phenotypic phases. As a consequence, a large portion of the 
work studying Bordetella physiology and pathogenesis has been focused on understanding the 
BvgAS system, and little is known about how other gene regulatory mechanisms contribute to 
Bordetella survival and pathogenesis. By demonstrating that the PlrSR two-component system 
(TCS) is required for BvgAS to become and remain fully active during infection in the LRT, this 
work begins to shed light on how Bordetella uses multiple TCSs to optimize bacterial virulence 
within the mammalian host, challenging the currently held dogma in the field.  
An improved vaccine, capable of preventing transmission of Bordetella, is especially 
critical for the global population to combat the effects of pertussis disease. Efforts to design a 
vaccine that generates a protective immune response are required. The inclusion of new vaccine 
components, not present in the current vaccines, would improve vaccine-generated immunity, 
even within individuals previously vaccinated with the current acellular vaccine. By 
demonstrating that PlrS is required for Bordetella persistence in the LRT even when BvgAS is 
rendered constitutively active, this work suggests the presence of BvgAS-independent, PlrS-
dependent virulence factors that are critical for bacterial survival in the trachea and lungs. Our 
current data support a model in which PlrS senses conditions present in the LRT and activates 
PlrR, which controls expression of genes required for the maintenance of BvgAS activity and for 
essential BvgAS-independent functions. In addition to providing a major advance in our 
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understanding of virulence regulation in Bordetella, these results indicate the existence of 
previously unknown virulence factors that may serve as new vaccine components and therapeutic 
or diagnostic targets. 
    While much is known about the BvgAS phosphorelay and transcriptional control of the 
BvgAS regulon, the natural signals that impact BvgS activity and the mechanism by which these 
signals are perceived and integrated by this system are unknown. As a result of our observation 
that maintenance of BvgS kinase activity in the LRT requires PlrSR, we were motivated to 
investigate which BvgS signal perception domain is required for this dependency. While the 
periplasmic venus fly-trap domains of BvgS have been implicated in responding to so-called 
modulating signals in vitro (nicotinic acid and MgSO4), a role for the cytoplasmic Per-Arnt-Sim 
(PAS) domain in signal perception has not previously been demonstrated. By comparing B. 
bronchiseptica strains with mutations in the PAS domain-encoding region of bvgS with wild-
type bacteria in vitro and in vivo, we found that although the PAS domain is not required to sense 
modulating signals in vitro, it is required for the inactivation of BvgS that occurs in the absence 
of PlrS in the LRT of mice, suggesting that the BvgS PAS domain functions as an independent 
signal perception domain. Our data also demonstrate that the BvgS PAS domain is important for 
controlling absolute levels of BvgS kinase activity and the efficiency of the response to 
modulating signals in vitro. To the best of our knowledge, our results are the first to indicate that 
BvgS is capable of integrating sensory inputs from both the periplasm via the VFT domains and 
from the cytoplasm via the PAS domain to control precise gene expression patterns in diverse 
environmental conditions. These findings are significant as they illuminate a previously 
unappreciated sensory integration mechanism and mode of regulation of BvgAS, which has been 
a paradigm of TCS regulation for more than 30 years.   
 
119 
How PlrSR influences the activity of BvgAS in the LRT remains unknown and is a 
current area of investigation of our laboratory. Based on our data and that of others, we 
hypothesize that PlrSR controls the expression of HACOs encoding genes, the products of which 
are required for bacterial respiration and maintenance of BvgAS activity in the LRT. Although B. 
bronchiseptica has seven putative cytochrome oxidase-encoding loci, little is known about if or 
how or when these respiratory enzymes influence Bordetella physiology or pathogenesis. We 
have discovered that two bd-type HACOs are required for maximum Bordetella colonization of 
the LRT in mice, however, our results suggest that additional respiratory enzymes may also be 
required. We hypothesize that these may include low affinity cytochrome oxidases. BvgAS 
kinase activity does not appear to be affected by the absence of HACOs nor have we found 
evidence that PlrSR controls the expression of HACO encoding genes, but, further investigation 
is required to confirm these findings. Regardless of whether our hypothesis is correct, this work 
will provide a foundation for further study into how cytochrome oxidases contribute to 
Bordetella respiration and pathogenesis. If our hypothesis is correct and BvgAS activity is 
influenced by the function of cytochrome oxidases, our results would be the first to identify a 
biologically relevant system with the capability of influencing BvgAS activity.  
Upon completion of this body work, a number of outstanding questions remain, many of 
which are focused on understanding more about the PlrSR system and what important processes 
this system regulates in Bordetella. PlrSR is a member of the NtrYX family of TCS. Although 
NtrXY systems are prevalent in proteobacteria, little is known about how these systems function. 
By continuing to studying PlrSR in Bordetella, our future work will not only impact the 
Bordetella field, but may also provide insight into how NtrYX-like systems in other bacteria 
function. We are interested in answering many of the following questions regarding PlrSR. 
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These questions include but are not limited to: What does PlrS sense?, Which sensory perception 
domains are important for PlrS function?, Why does PlrR appear to be essential?, and Is PlrS 
capable of phosphorylating and dephosphorylating PlrR? The most significant question regarding 
PlrSR are what genes comprise the PlrSR regulon and which of these genes encode potential 
virulence factors or products that link PlrSR with BvgAS regulation during infection. To try to 
answer this pressing question, we plan to continue investigating the regulation and influence of 
cytochrome oxidases using B. bronchiseptica. In addition, our collaborators are carrying out a 
screen to identify genes expressed by Bordetella only in the LRT. Based on these results, we 
plan to evaluate which, if any, are under the control of PlrSR. Subsequently, these newly 
identified genes can be evaluated for their contribution to Bordetella pathogenesis in hopes of 
identifying new virulence factors and therapeutic targets that may help to improve vaccine and 
remedial strategies against pertussis disease.        
 
 
